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Histone deacetylase inhibitors (HDACi) are anti-cancer drugs that primarily act
upon acetylation of histones, however they also increase levels of intracellular reactive
oxygen species (ROS).

We hypothesized that agents that cause oxidative stress

might enhance the efficacy of HDACi.

To test this hypothesis, we treated acute

lymphocytic leukemia cells (ALL) with HDACi and adaphostin (ROS generating agent).
The combination of two different HDACi (vorinostat or entinostat) with adaphostin
synergistically induced apoptosis in ALL. This synergistic effect was blocked when
cells were pre-treated with the caspase-9 inhibitor, LEHD. In addition, we showed that
loss of the mitochondrial membrane potential is the earliest event observed starting at
12 h. Following this event, we observed increased levels of superoxide at 16 h, and
ultimately caspase-3 activation. Pre-treatment with the antioxidant N-acetylcysteine
(NAC) blocked ROS generation and reversed the loss of mitochondrial membrane
potential for both combinations.

Interestingly, DNA fragmentation and caspase-3

activity was only blocked by NAC in cells treated with vorinostat-adaphostin; but not
with entinostat-adaphostin. These results suggest that different redox mechanisms
are involved in the induction of ROS-mediated apoptosis. To further understand these
events, we studied the role of the antioxidants glutathione (GSH) and thioredoxin (Trx).
We found that the combination of entinostat-adaphostin induced acetylation of the
v

antioxidant thioredoxin (Trx) and decreased intracellular levels of GSH. However, no
effect on Trx activity was observed in either combination. In addition, pre-treatment
with GSH ethyl ester, a soluble form of GSH, did not block DNA fragmentation.
Together these results suggested that GSH and Trx are not major players in the
induction of oxidative stress. Array data examining the expression of genes involved
in oxidative stress demonstrated a differential regulation between cells treated with
vorinostat-adaphostin and entinostat-adaphostin.

Some of the genes differentially

expressed between the combinations include aldehyde oxidase 1, glutathione
peroxidase-5, -6, peroxiredoxin 6 and myeloperoxidase.

Taken together, these

experimental results indicate that the synergistic activity of two different HDACi with
adaphostin is mediated by distinct redox mechanisms in ALL cells. Understanding the
mechanism involved in these combinations will advance scientific knowledge of how
the action of HDACi could be augmented in leukemia models. Moreover, this
information could be used for the development of effective clinical trials combining
HDACi with other anticancer agents.
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CHAPTER 1: INTRODUCTION
1.1

Leukemia
Despite improvements in medicine, cancer remains one of the leading causes

of death in the U.S. It is estimated that in 2012, about 1.6 million new cases of cancer
will be diagnosed in the U.S. and one of four deaths will be due to cancer [3]. Among
these new cases, approximately one third will be amongst the pediatric population.
Within this population, leukemia is the cancer with the highest incidence and mortality
among pediatric patients [3].
Leukemia by definition is a cancer of the blood and bone marrow cells [4]. This
type of cancer is usually classified based on the cell type or by how rapidly the disease
progress or develops.

In the case of the cell type, these can be: lymphocytic

leukemias, which are developed from the lymphoid precursors or myeloid leukemias,
which are developed from the myeloid precursors (Figure 1). In terms of disease
progression, these can be divided into acute versus chronic leukemias. The term
acute refers to a rapid tumor cell proliferation and accumulation of immature or blast
cells (lymphoblasts or myeloblasts).

In the case of chronic leukemias, the

predominant tumor cells are mature blood cells and are characterized by a slow
growth rate. Based on this basic definition there are four major types of leukemias:
acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic
leukemia (CLL) and chronic myeloid leukemia (CML) [4].
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Figure 1. Origin of the major four classes of leukemias. Normal hematopoiesis
(the formation of the blood) is a process where the hematopoietic stem cells (HSCs)
differentiate into two common lineages: common lymphoid progenitors (CLP) and
common myeloid progenitors (CMP). Acute Lymphoblastic Leukemia (ALL) and
Chronic Lymphoblastic Leukemia (CLL) are derived from the CLP. In contrast,
Acute Myeloid Leukemia (AML) and Chronic Myeloid Leukemia (CML) are
derived from the CMP. Adapted from Irwin M.E. et al. Antioxidant and Redox
Signaling 2012 Sep 28 [Epub ahead of print] [1].
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The most common type of leukemias in children are acute leukemias, with ALL
being the most common subtype. ALL comprises 80% of all childhood leukemias
while AML accounts for approximately 18%. In terms of chronic leukemias, only about
2% of CML is diagnosed in children and CLL is rarely reported in pediatric patients [5].
The major cause of childhood leukemias has been linked to genetic factors and/or
environmental factors.

Some of the genetic factors include hyperdiploidy,

hypodiploidy, chromosomal translocations and deletions [6].

In addition to these

genetic abnormalities, several studies have found an association between genetic
syndromes and the development of childhood leukemia. Some of these syndromes
include: Down syndrome, neurofibromatosis and schwachman syndrome [7-9].
Environmental factors like in utero exposure to ionizing radiation; exposure to certain
chemicals like benzene, hydrocarbons and pesticides has also been linked to the
development of childhood leukemias [10, 11].
ALL is divided into different subtypes based upon morphological and
cytogenetic features. In terms of morphological changes, ALL can be divided into
three subtypes: ALL-L1, -L2 and -L3 [4]. In the L1 subtype the lymphoblast is relative
small with a high nuclear to cytoplasmic ratio and small nucleoli. In L2 the lymphoblast
is larger with low nuclear to cytoplasmic ratio and large nucleoli. In L3 the lymphoblast
resemble a mature B cell with large vacuoles and nucleoli. Each of these subtypes
are further divided by immunologic types: pre-B cells and pre-T cells [4].
Advances in the molecular genetics field have resulted in more accurate
classification of ALL based on their genetic abnormalities.

These cytogenetic

classifications have helped to understand better the prognosis of ALL. Some of the
cytogenetic features with good prognosis observed in ALL include: hyperdiploidy
(more than 50 chromosomes) and translocations like t(12;21)(p21;q22). Otherwise
3

cytogenetic features with intermediate and poor prognosis include: hypodiploidy (less
than 45 chromosomes), del(6q), del(9p), t(9;22)(q34;q11) and t(8;14)(q24;q32) [4].
During the past few decades, great advances in the treatment of pediatric
leukemia has resulted in an 80% cure rate [12]. The treatment for pediatric leukemias
varies according to age, disease stage, subtype and myeloid versus lymphoid origin.
Standard treatment for leukemia includes chemotherapy, radiation, bone marrow
transplantation, stem cell transplantation or a combination of these treatments [13].
Usually chemotherapy regimens are divided in three major stages or phases:
induction, consolidation and maintenance phase [13]. During induction phase, the
major goal is to kill the majority of the cancer cells. The duration of this phase is
around three to eight weeks and during this time different chemotherapies are
administered. The second phase is consolidation where the major goal is to eliminate
any remaining cancer cells.

The duration of this phase is around a few months.

Finally after remission of the disease, the third phase of maintenance begins. This is a
less intense phase and may last around one to two years. The major goal in this
phase is to decrease the probability of relapse.
During all these phases different types of drugs are administrated.

Since

cancer cells are characterized by abnormal proliferation, the majority of the drugs used
work by disrupting cell proliferation and progression of cell cycle. Some of the drugs
most

commonly

used

include

anthracyclines,

topoisomerase

inhibitors

and

antimetabolites [13]. Anthracyclines like daunorubicin and doxorubicin are commonly
used during induction phase and work by intercalating between base pair of the DNA
inhibiting its synthesis. In addition some of these drugs can act as topoisomerase
inhibitors, in this case the agent binds to the topoisomerase molecule blocking its
ability to bind to the DNA, which ultimately results in DNA damage and cell death. In
4

the case of antimetabolites like methotrexate and thioguanine, these drugs work by
preventing purines and pyrimidines to incorporate into DNA during S phase,
preventing cell division and growth.
Even when cure rates are promising, 20% of pediatric patients with ALL are not
curable due to specific molecular subtypes, which confer resistance to the current
available chemotherapy. Furthermore, studies have demonstrated that survivors from
pediatric leukemias tend to develop treatment related side effects later in life [14].
Some of the side effects observed include cardiotoxicity and the development of
secondary cancers. In addition, even though ALL affects mostly pediatric patients,
there is a group of adults that will develop ALL during the course of their life. The
prognosis in these patients is not as promising as in children, resulting in a survival
rate less than 40% [4]. For these groups of patients, the development of new selective
drugs and strategies for the treatment of ALL is of great importance.
Conventional therapies, like the ones mentioned before, kill cancer cells by
inhibiting growth. However, this inhibition is not specific for cancer cells; these drugs
can also target normal cells that are actively dividing.

Therefore, development of

specific targeted therapies based on differences between cancer and normal cells is of
utmost importance. The identification of specific subtypes and alterations in cancer
cells have helped in the development of new targeted therapies. Some of the targeted
therapies that have shown promise for the treatment of leukemias include: kinase
inhibitors, histone deacetylase inhibitors, proteasome inhibitors and Bcl-2-targeted
agents [15]. Interestingly, in addition to inhibiting their specific targets, some of these
agents have been shown to alter the redox state of cancer cells [15, 16]. The following
section will be dedicated to introduce the concept of oxidative stress and its
implications for the treatment of cancer.
5

1.2

Oxidative stress
1.2.1 Redox homeostasis and oxidative stress
Redox homeostasis is defined as the balance between the production and

elimination of oxygen-containing molecules named reactive oxygen species (ROS)
[16]. ROS are highly reactive molecules that include radical species like superoxide
and hydroxyl radical and non-radical molecules like hydrogen peroxide.

The

production of ROS within the cell is the result of different exogenous and endogenous
stimuli.

Exogenous sources of ROS include exposure to different chemicals and

radiation. The major endogenous source of cellular ROS is the mitochondria, where
superoxide is generated by the electron-transport chain and subsequent reactions
result in the production of hydrogen peroxide and hydroxyl radical [16].

Other

endogenous sources of ROS include the activation of oxidases including NADPH
oxidase, xanthine oxidase and monoamine oxidase [16].
Proper redox homeostasis plays a critical role for the normal function of the cell.
To maintain redox homeostasis, cells contain different antioxidant systems that help to
eliminate excessive levels of ROS. Some of these antioxidants include enzymes like
superoxide dismutase (SOD), which catalyze the conversion of superoxide to
hydrogen peroxide and catalase.

Subsequently catalase, another antioxidant,

catalyzes the conversion of hydrogen peroxide to water and oxygen.

Other non-

enzymatic antioxidants like glutathione (GSH) and thioredoxin (Trx) play important
roles in the elimination of ROS (Figure 2) [16].
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Figure 2. Sources of ROS and its cellular response. Production of ROS
within the cell can be the result of endogenous or exogenous sources. To
maintain homeostasis in the levels of ROS, cells contain antioxidant
defense mechanisms. An increase in antioxidants like superoxide
dismutase (SOD), catalase (CAT), glutathione (GSH) and thioredoxin (Trx)
help the cells to maintain homeostasis. When levels of ROS decrease or
increase, different physiological functions can be affected.
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Glutathione (GSH)
GSH is a tripeptide consisting of glutamate, cysteine and glycine. These amino
acids are assembled into active GSH through the enzymatic action of γglutamylcysteine synthetase and GSH synthetase [17]. This molecule is the most
abundant thiol containing peptide within the cells. Its major function is to work as a
reducing agent and ROS scavenger. A reactive sulfhydryl group drives its antioxidant
function. In addition to working as an antioxidant, GSH plays different roles within the
cell including metabolism of xenobiotics, cell-cycle regulation, control of mitochondrial
mediated cell death, modulation of immune response and regulation of protein function
and gene expression via thiol-disulfide exchange reactions [17]. Due to its important
role in cell physiology, alterations in GSH levels have been associated with the
development of different diseases, including neurodegenerative disorders, diabetes,
cardiovascular diseases and cancer [18, 19].
GSH, serving as an electron donor, can reduce disulfide bonds-containing
proteins to cysteines.

As a ROS scavenger, GSH works by converting reactive

species such as hydrogen peroxide to less reactive molecules.

In this process,

glutathione peroxidase (GPX) catalyzes the conversion of GSH to the oxidized
glutathione disulfide (GSSG). Subsequently, GSSG can be reduced back to GSH by
glutathione reductase in a reaction that requires NADPH as an electron donor (Figure
3) [17]. The ratio of GSH to GSSG within the cell is regularly used as a measurement
of cellular toxicity [20]. In addition to functioning as an antioxidant, GSH also plays
important roles in the generation of other antioxidants like vitamin C and E [17].

8

Figure 3. GSH antioxidant reaction. Superoxide (O2-) is converted to
hydrogen peroxide (H2O2) by a reaction catalyzed by superoxide
dismutase (SOD). Using reduced glutathione (GSH) as a substrate,
glutathione peroxidase (GPX) converts H2O2 to water (H2O). During this
reaction GSH is oxidized to glutathione disulfide (GSSG). GSSG can be
reduced back to GSH by glutathione reductase using NADPH as a
substrate.
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Thioredoxin (Trx)
Trx is another important thiol containing antioxidant, which plays a role in
maintaining redox homeostasis within the cell. Human Trx was originally cloned as an
adult T cell leukemia (ATL)-derived factor; produced by a HTLV-1 transformed T cell
line ATL-2 cells [21].

Trx is a 12 KDa selenoprotein containing two redox-active

cysteines and a conserved active site. The Trx system is primarily composed of two
isoforms of Trx, which include cytosolic Trx1 and mitochondrial Trx2. Two other major
members of this family include Trx reductase-1 and -2 (TrxR-1 & TrxR-2), which are
localized in the cytosol or the mitochondria respectively [22]. To maintain homeostasis
Trx-binding protein 2 (TBP-2), also known as Trx-interacting protein (TXNIP), works as
a negative regulator of Trx. This molecule binds directly to Trx, resulting in decreased
antioxidant capacity [23].

Similar to GSH, Trx aids in the removal of hydrogen

peroxide and plays an important role in reducing disulfide bond-containing proteins. In
this process, peroxiredoxin catalyzes the conversion of reduced Trx (Trx-S2) to its
oxidized form (Trx-(SH)2).

Then Trx-(SH)2 can be reduced back to Trx-S2 by

thioredoxin reductase (TrxR) using NADPH as an electron donor [22] (Figure 4A).
In addition to working as an antioxidant, Trx has pleiotropic functions within the
cell. Trx has been known to act as a growth factor, activator of transcription factors
and apoptotic controller [22]. This pleiotropic function is driven by its interaction with
other proteins like the transcription factor NF-κB and the apoptosis signal-regulating
kinase 1 (ASK-1) (Figure 4B). In the case of NF-κB, reduced Trx can bind to NF-κB,
helping in its translocation to the nucleus and binding to DNA, which results in gene
expression (Figure 4C) [24, 25]. This binding to the DNA is regulated by the reduction
of a disulfide bond in cysteine 62 of the p50 subunit of NF-κB [26]. As an apoptotic
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controller, reduced Trx can bind to ASK-1, which is required for TNF-α-induced
apoptosis [27, 28]. The binding to ASK-1 results in inhibition of ASK-1 dependent
apoptosis (Figure 4B). In the presence of TNF-α or generation of ROS, Trx is oxidized
resulting in dissociation of ASK-1, subsequently leading to its activation and apoptosis.

Figure 4. Pleiotropic effect of Trx. A) Trx works as a ROS
scavenger by removing hydrogen peroxide (H2O2). This
reaction is catalyzed by peroxiredoxin. B) Trx also regulates
apoptosis by binding to apoptosis signaling-regulating kinase-1
(ASK-1). C) Reduced Trx can bind directly to NFΚB affecting
gene expression.

The balanced production of ROS and antioxidants is important to maintain redox
homeostasis and for the proper function of the cell.

An imbalance between

antioxidants and oxidants results in oxidative stress, which can affect cell survival in
different forms. Under oxidative stress, elevated levels of ROS can result in damage
of lipid membranes, proteins and DNA [16].

Alterations in cellular metabolism and

antioxidants levels have been associated with different human diseases including
neurodegenerative diseases, cardiovascular disorders and cancer [16].

11

In the next section we will discuss the different redox alterations that can result in the
development of cancer, focusing primarily on ALL.

1.2.2 Redox alterations in leukemia and its implication in cancer therapy
Several studies have demonstrated that cancer cells, including the cells of
hematological malignancies, have higher levels of ROS than normal cells [29, 30].
These elevated levels of ROS have been associated with tumor initiation, promotion
and maintenance of the cancer cells [16]. The exact mechanisms responsible for the
redox alterations observed in leukemic cells are not clear. Several studies suggest
that elevated levels of ROS in leukemia can be the result of oncogenic activation. The
BCR/ABL oncogene, which is expressed in CML and a subtype of ALL, has been
demonstrated to alter redox homeostasis by increasing the levels of peroxide and
superoxide [31, 32]. In addition to BCR/ABL, other alterations like overexpression of
the antiapoptotic protein BCL-2 has been associated with redox control in leukemia.
BCL-2 can function as an oncogenic signal affecting the production of GSH resulting in
redox alteration in ALL cells [33, 34]. In this case, inhibition of BCL-2 with the agent
ABT-737 in ALL cells results in GSH depletion and increase oxidative stress [34].
Another explanation for the elevated levels of ROS observed in leukemias is the
hyperactivation of endogenous sources of ROS such as the mitochondrial electron
chain. Mutations in mitochondrial DNA have been observed in different leukemias [35,
36].

These mutations can alter the electron transport chain resulting in oxidative

stress. Furthermore, ROS production by complex I of the mitochondrial electron chain
was reported as a survival factor in ALL patient samples [37].
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As observed in other cancer cells, leukemia cells appear to have altered
expression or dysregulation of antioxidant proteins. This dysregulation can result in
elevated expression of antioxidants, which allows leukemic cells to readily cope with
the increased ROS production.

Antioxidants that have been reported to be up-

regulated in ALL include GSH and Trx.

Different studies have compared healthy

donor samples with leukemia patient samples. The results demonstrated higher GSH
levels in CLL, AML and ALL patients compared to healthy individuals [38, 39]. Several
studies have also associated elevated levels of GSH with resistance to chemotherapy
in ALL cells [40, 41]. Furthermore, there is a correlation between elevated GSH and
an increased risk of relapse in pediatric patients with ALL [42].
Trx dysregulation has also been demonstrated to alter the redox status in
leukemias.

Trx is upregulated in leukemias resulting in sustained growth and

decreased apoptosis [43]. Studies in acute leukemia patient samples have found a
correlation between elevated Trx mRNA expression with relapse and poor prognosis,
suggesting Trx is a negative prognostic indicator [44]. The activation of Trx pathways
in acute leukemia seems to be different between leukemia types. In AML patient
samples, TBP-2 is overexpressed resulting in decreased Trx activity and elevated
ROS [45]. In contrast, TBP-2 is lost in ALL and consequent upregulation of Trx is
observed. In this study re-expression of TBP-2 resulted in growth inhibition [46].
On the other hand, dysregulations resulting in decreased levels of antioxidants
can lead to elevation of ROS levels. Consequently this elevation in ROS can result in
proliferation and genomic instability.

SOD, is an antioxidant, which catalyzes the

conversion of superoxide to hydrogen peroxide and catalase. Studies have reported
decreased levels of SOD in lymphocytes from ALL patients when compared to healthy
donors samples [47, 48]. Another example of decreased levels of antioxidants in
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leukemia includes catalase.
hydrogen peroxide.

Catalase is an enzyme involve in the elimination of

ALL cells have lower levels of catalase activity compared to

normal cells. These results were associated with an increase in hydrogen peroxide
and genomic instability [48].
These redox alterations in cancer cells have been exploited for the identification
and development of new specific and selective anticancer treatments. It has been
hypothesized that if a chemotherapeutic agent has the ability to push ROS levels in
malignant cells past a particular threshold, cell death will occur [29]. In contrast, this
increase in ROS will not cause major damage to normal cells due to their low basal
ROS levels. Some of the chemotherapeutic agents that have been shown to induce
oxidative stress mediated apoptosis in leukemia cells include: proteasome inhibitors,
Bcl-2-targeted agents, kinase inhibitors and HDACi [49, 50]. The following section
focuses on HDACi as a targeted agent inducing oxidative stress mediated apoptosis.
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1.3

Histone deacetylase inhibitors (HDACi)
1.3.1 Rationale for the development of HDACi
Cancer has traditionally been defined as a genetic disease where genetic

alterations have been considered as a major cause of carcinogenesis [51].
Carcinogenesis or development of cancer consists of three major steps: initiation,
promotion and progression. During the initiation step, genetic alteration or mutations
result in the formation of cancer cells. In the promotion step, the cancer cells are
clonally expanded and finally in the progression step additional genetic mutations can
be acquired.

Mutations in oncogenes and tumor suppressor genes may result in

changes in gene expression, which has been attributed to the development of cancer.
In the past few years, completion of the human genome sequence has led to
the study of epigenetics.

Epigenetics is defined as a heritable change in gene

expression without alterations in the underlying DNA sequence [52]. Several studies
have demonstrated that as genetic alterations, epigenetic changes in gene expression
can be involved in the process of carcinogenesis [53]. While many genetic defects,
such as gene deletions, cannot be reversed, many epigenetic abnormalities in cells
can be reversed, making epigenetic changes attractive targets for the development of
new therapies. Two of the most common epigenetic alterations observed in cancer
are DNA methylation and post-translational modification of histones.
DNA methylation is the most studied epigenetic alteration in cancer.

The

process of DNA methylation involves DNA methyltransferases (DNMTs), which
transfer methyl groups from S-adenosylmethionine to cytosines that are part of CpG
dense regions or better known as CpG islands [54]. The methylation of these regions
is associated with transcriptional repression. Studies have demonstrated that cancer
cells exhibit different patterns of DNA methylation in genes involved in important cells
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functions like cell cycle regulation, DNA repair, and tumor suppression and/or histone
modification compared to normal cells [55-57].
The second most studied epigenetic alteration includes the post-translational
modifications of histones. Histones are proteins found predominantly within the cell
nucleus and the major role is to package the DNA to form the nucleosome, which is
the basic building block of the chromatin. Histone modifications include: methylation,
acetylation, phosphorylation, ubiquitination and ADP-ribosylation [58].

These

modifications give the nucleosome a structure where different processes like
transcription, DNA replication, and DNA repair take place.
Histone acetylation has been identified as a target for the treatment of cancer.
The acetylation of histones is a dynamic process, which include two different enzymes:
the histone acetyltransferases (HATs) and histone deacetylases (HDACs) (Figure 5).
The HATs are divided into five families, which include the GNAT superfamily, the Myst
family, p300/CBP, TAFII 250 and nuclear receptors [59]. These enzymes use acetylCoA to add acetyl groups to lysine residues on histone tails.

The amine groups

present in lysine confer a positive charge to histone tails [60]. This positive charge
interacts with the negative charge found on the phosphate group of the DNA chain.
Histone acetylation changes the amine groups to amides, which neutralizes the
positive charge on the histone tail resulting in decreased ability of histones to bind the
DNA chain [60]. The decrease interaction of histone with the DNA chain confers a
more relaxed chromatin structure allowing different transcription factors and molecular
complexes to interact with the chromatin resulting mainly in gene transcription [61].
In contrast, the HDACs, which are divided into four classes (Figure 6), remove
acetyl groups. The removal of acetyl groups increases the positive charge of histone
which then can interact with the DNA chain resulting in a more compacted chromatin,
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which is associated with transcriptional repression [60].

In addition to histones,

HDACs can acetylate lysine residues on non-histone proteins like transcription factors,
chaperone proteins and other proteins involved in cell signaling [62]. This acetylation
in non-histone proteins can interfere with binding, activity or stability of the protein.

Figure 5. Chromatin acetylation. Acetylation of histone tails is driven by
the homeostasis between histone acetyltransferases (HATs) and histone
deacetylases (HDACs) enzymes. HATs add acetyl groups to the histone
tails allowing a more relax chromatin structure. HDACs remove the acetyl
groups resulting in a more compacted chromatin.

Different studies have demonstrated the association of abnormal expression of
HDAC with cancer [63].

Histone hypoacetylation has been associated with the

silencing of important genes like tumor suppressor genes and genes involved in cell
differentiation and apoptosis [64]. Also, loss of acetylation of lysine 16 in histone H4
has been associated with cancer [65].

Furthermore, studies suggest a possible

relation between histone modification patterns and poor outcome in different types of
cancer [56, 66].

As results of all these observations, new therapies that target

epigenetic changes in cancer have been developed. One of these emerging new
therapies includes the histone deacetylase inhibitors (HDACi).
HDACi are a group of compounds that block the activity of HDACs resulting in
hyperacetylation of histones or non-histone proteins. This group of inhibitors includes
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natural and synthetic derivates, which are grouped on the basis of chemical structure
and their ability to inhibit the activity of specific HDACs (Figure 6).

Figure 6. HDAC enzyme family. HDAC are divided in four classes based
on their catalytic domain and cellular localization Class I, II a, II b and IV.
Different HDAC inhibitors have been developed to target specific HDAC.
Pan-HDAC inhibitors include: vorinostat, Trichostatin A (TSA) and
panobinostat (LBH589). Inhibitors selective for class I HDAC include:
entinostat and depsipeptide. Class I and II a inhibitors include: valproic acid
(VPA), butyrate and trapoxin. More specific inhibitors like tubacin inhibit
specifically HDAC 6, a member of the Class II b.

These compounds were discovered through different observations where
treatment with dimethyl sulfoxide (DMSO) and the antibiotic trichostatin A (TSA)
induced cell differentiation and cell cycle arrest in murine erythroleukemia cells [67,
68]. More detailed observations demonstrated that TSA targets HDACs resulting in
their inhibition and consequently histone hyperacetylation [68].

Based on these
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observations different efforts have been directed to develop agents with similar activity
observed by DMSO and TSA treatments.

Presently, there are approximately six

classes of HDACi, including short-chain fatty acids, hydroxamic acids, and benzamide
[69].

The efficacy of HDACi in inhibiting the enzymatic activity of HDACs varies

between classes (Figure 6).
Vorinostat, or originally named by its chemical structure as suberoylanilide
hydroxamic acid (SAHA; Figure 7) is the first HDACi approved by the U.S. Food and
Drug Administration for treatment of cutaneous T-cell lymphoma.

Figure 7. Chemical structure of vorinostat. Vorinostat or
SAHS is a hydroxamic acid, which is a pan-HDAC inhibitors.
www.lclabs.com

This agent was first identified as an HDACi by Richon et al., where they reported
that vorinostat inhibited the activity of HDACs 1 and 3 in cancer cells [70]. Subsequent
studies demonstrated that vorinostat works as a pan-HDAC inhibitor blocking the
enzymatic activity of class I, II and IV HDAC [71]. In vitro studies have demonstrated
that vorinostat has different biological effects including cell cycle arrest, cell
differentiation, induction of apoptosis, angiogenesis inhibition and modulation of
immune response [71]. In addition to increasing histone acetylation, vorinostat has the
ability to induce non-histone proteins. Increased acetylation of different transcription
factors like p53, E2F and HIF-1α and cytoplasmic proteins like tubulin and HSP90
have been associated with the mechanism by which this agent induces cell cycle
arrest and cell death [71]. The anticancer effect of vorinostat has been also tested in
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in vivo models. In a xenograft model of prostate cancer, administration of 50 mg/kg
vorinostat resulted in significant suppression of tumor growth when compared to mice
receiving vehicle alone [72]. In an in vivo model of ALL, vorinostat was administrated
at different doses including 50, 100 and 150 mg/kg resulting in growth suppression of
the xenograft tumors [73].
Entinostat is a novel HDACi, which is currently in clinical trials for the treatment
of different cancers. Entinostat, previously known as MS-275, is a benzamide with
selective inhibition of class I HDAC, specifically HDAC 1, 2 and 3.

Figure 8. Chemical structure of entinostat. Entinostat or MS-275
is a benzamide which inhibits class-I HDACs. www.exchemistry.com

Different studies have demonstrated that this agent induces cell cycle arrest, cell
differentiation and apoptosis in cancer cells [74]. In vitro studies using leukemia cell
lines and patient samples demonstrated that lower doses of entinostat induced p21dependent growth arrest.

In contrast, treatment with higher concentrations of this

agent induced apoptosis in these samples [75]. This agent also has the ability to
target leukemic oncogenes like FLT3-ITD. FLT3-ITD is an oncogene associated with
acute leukemias. In a study using FLT3 positive leukemia cells, entinostat induced
acetylation of HSP90 and ubiquitination of FLT3 resulting in degradation of FLT3 and
cell death [76]. Another mechanism by which this agent can induce growth arrest is
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through the Akt pathway. Entinostat blocked the Akt signaling in AML cells resulting in
growth arrest and cell differentiation [77]. In vivo studies using different cancer model,
including sarcoma and neuroblastoma, demonstrated that administration of entinostat
inhibited the growth of established tumors [74].
In general, the rationale behind the development of HDACi is that these drugs
will increase acetylation of histones, which may lead to the reactivation of important
genes involved in cell proliferation, cell differentiation, modulation of the immune
response and induction of cell death. Interestingly, several studies have demonstrated
that HDACi also induce oxidative stress as one of its mechanism of action.

The

following two sections will discuss the mechanism by which HDACi induce apoptosis
and oxidative stress.

1.3.2 Induction of apoptosis by HDACi
In general, HDACi have been demonstrated to induce apoptosis in different
types of cancer cells, including leukemic lymphocytes and myelocytes [78]. Apoptosis
is defined as programmed cell death, which is physiological necessary to eliminate
unwanted cells within an organism [79]. This type of cell death is characterized by
changes in the cells that include: cell shrinkage, disruption of the mitochondria, DNA
fragmentation and the appearance of apoptotic bodies. These apoptotic bodies are
recognized by phagocytes, which finally engulf and eliminate the dead cell.
The process that directs all these changes within the cells is very complex and
organized. There are two major pathways by which the cells undergo apoptosis: the
extrinsic pathway (death-receptor pathway) and the intrinsic pathway (mitochondrial
pathway) [79]. Both of these pathways are driven by different proteases better known
as caspases (cysteine-directed aspartate specific proteases).

These enzymes
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recognize and cleave their substrates at tetra-peptide sites that have specific
sequences.

Caspases are divided into initiators (activator) caspases, effector

(executioner caspases) depending on their function [79].
The extrinsic pathway is mainly driven by the initiator caspase-8. This pathway
is initially activated by the binding of FasL, TRAIL or TNF-α to death receptors
localized at the cell membrane. This binding results in the oligomerization of the death
receptor and the internal recruitment of the adaptor protein FADD with the caspase-8.
The complex of FADD and caspase-8 form the death-inducing signaling complex
(DISC), which initiates the apoptotic process through the cleavage of caspase-8 or 10. The activation of caspase-8 or -10 induces the activation of the effector caspases3 or -7, which ultimately results in all the biochemical and morphological changes
associated with apoptosis [79].
The intrinsic pathway is regulated by pro-apoptotic and anti-apoptotic proteins.
Pro-apoptotic proteins like Bax can activate the intrinsic pathway by binding to the
mitochondrial membrane.

This binding results in mitochondrial membrane

perturbation and the release of cytochrome c, which then associates with procaspase9 and the adaptor protein Apaf-1 to form the apoptosome. The apoptosome, activates
the initiator caspase-9 which ultimately cleaves and activates the executors, caspase3 or -7 resulting in cell death. The intrinsic pathway can also be activated by the
extrinsic pathway. In this case the pro-apoptotic protein Bid serves like a link between
the two pathways. Bid is cleaved and activated by caspase-8 resulting in the fragment
tBid, which then binds to the mitochondrial membrane resulting in the activation of the
intrinsic pathway.

Depending on the target cell and the specific HDACi, different
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studies have demonstrated that HDACi can induce apoptosis in cancer cells by the
two-apoptotic pathways, the extrinsic and the intrinsic pathway.
In terms of the extrinsic pathway, in vitro studies using AML cell lines and patient
blast samples, demonstrated that vorinostat and entinostat induce the gene
expression of TRAIL by directly activating the TNFSF10 promoter, which consequently
activates the extrinsic apoptotic pathway by binding to death receptors [80]. However
this effect was not observed in normal CD34+ cells, which were resistant to HDACi
induced-apoptosis [80]. Furthermore, in vivo studies validated the previous
observations, demonstrating that suppressing TRAIL and Fas by siRNA resulted in
significant reduction in apoptosis after treatment with HDACi [81]. In addition to these
observations, Guo et al. demonstrated that treatment of ALL cells with the HDACi
LAQ824 increases the mRNA and protein expression of the death receptors DR5 and
DR4 [82]. In contrast, studies using lymphoma cells found that knockout of TRAIL or
inhibition of caspase-8 activation have no effect on the apoptotic induction by LAQ824
and LBH-589 [83]. These last observations suggest that the activation of the extrinsic
pathway by HDACi may be cell-type dependent. Other mechanisms by which HDACi
can activate the extrinsic pathway can be through the recruitment of FADD and
activation of caspase-8.

Treatment of TRAIL resistant CLL cells with TSA and

romidepsin resulted in sensitization of these cells to TRAIL induced apoptosis through
the recruitment of FADD and caspase-8 into the DISC [84].
In addition to the extrinsic apoptotic pathway, HDACi have demonstrated to
induce apoptosis through the intrinsic apoptotic pathway.

These drugs can

transcriptionally activate BH3-only proteins including Bid, Bad and Bim, which are
important proteins in the activation of the intrinsic pathway [85-87].
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Treatment of leukemia patient samples with vorinostat induced the cleavage of
caspase-8, -9 and -3. However, the overexpression of Bcl-2 in these cells resulted in
complete inhibition of vorinostat-induced apoptosis [88]. Further studies using an in
vivo model of Burkitt’s lymphoma, demonstrated that overexpression of Bcl-2 resulted
in resistance to HDACi, again validating the importance of the prosurvival Bcl-2 protein
[89]. Studies have demonstrated that HDACi can also induce the cleavage of Bid
resulting in disruption of the mitochondrial membrane, release of ROS and cytochrome
c and ultimately apoptosis in leukemia cells [87].
In addition to inducing apoptosis by the up- or down-regulation of apoptotic
related proteins, several studies have demonstrated that HDACi induces oxidative
stress in different types of cancer cells [87, 90, 91]. However the mechanisms by
which HDACi induce oxidative stress is not well understood. These studies suggest a
possible role of redox regulation in the efficacy of HDACi alone and in combination
with other anticancer agents. As presented in previous sections, redox alterations in
cancer cells can be used as a strategy to treat cancer. Understanding how agents like
HDACi can alter the redox status in cancer cells is of critical importance for the
development of more effective agents, in this case HDACi.

Furthermore

understanding of these mechanisms can help to anticipate possible drug resistance
and better design of clinical trials that include combinations of HDACi with other
anticancer agents. The following section will discuss the literature that support the
mechanisms by which different HDACi induce oxidative stress.
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1.3.3 Induction of oxidative stress by HDACi
The mechanisms by which HDACi induce oxidative stress is not well understood.
Two possible mechanisms have been reported. The first one reported vorinostat to
induce apoptosis by the expression of Bid, a pro-apoptotic protein, which resulted in
disruption of the mitochondria and consequent production of ROS (Figure 4A) [69].
The second mechanism involved the antioxidant thioredoxin (Trx).

Studies have

shown vorinostat to inhibit Trx as a mechanism by which oxidative stress may occur
[92]. An explanation for this Trx inhibition is that vorinostat increased the expression
of thioredoxin-binding protein (TBP-2), which binds and inactivates Trx (Figure 4B).
Furthermore, additional studies showed that non-transformed cells displayed higher
levels of Trx compared to transformed cells. Non-transformed cells with higher levels
of Trx were more resistant against HDACi. Otherwise, transformed cells with lower
levels of Trx were more sensitive to vorinostat and entinostat [93].
Interestingly, post-translational modifications of Trx, like glutathionylation [94],
have been shown to affect its activity. A recent study reports Trx to be acetylated by
vorinostat [62], however it is unknown if Trx acetylation affects its activity.

Trx

acetylation and consequent Trx inhibition may work as a novel mechanism of how
HDACi induce oxidative stress in cancer cells and will be tested in this dissertation.
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Figure 9. Proposed mechanism of ROS induction by HDACi. A) HDACi can
induce the expression of BID, which associates with the mitochondrial membrane
resulting in release of ROS. B) HDACi can induce the expression of TBP-2,
which binds to Trx inhibiting its activity resulting in ROS accumulation [2].
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1.3.4 HDACi in the clinic
As presented in previous sections, HDACi have gained widespread attention due
to its anticancer activity in preclinical studies. In addition, multiple clinical trials using
HDACi as a single agent and in combination with other chemotherapies have yielded
promising results. This section will discuss some of the clinical trials using HDACi.
Vorinostat was the first HDACi showing positive results in clinical trials. This
agent was approved for the treatment of cutaneous T-cell lymphoma. During phase I
and II trials, vorinostat was well tolerated and 30% of the patients enrolled in the trial
responded positively to the treatment [95]. These trials resulted in the approval of
vorinostat for the treatment of this type of cancer.

Recently, clinical trials using

vorinostat have evaluated its efficacy in different types of leukemias. A phase I trial of
vorinostat in AML patients demonstrated effective inhibition of HDAC activity in blood
and bone marrow samples [96].

A second phase I trial evaluated the maximum

tolerated dose (MTD) and the side effects of vorinostat in pediatric leukemia patients
[97]. The MTD reported in these patients was 230 mg/m2/d administrated orally and
the side effects included nausea, loss of appetite and fatigue.

Overall, this trial

concluded that the pharmacokinetics of vorinostat in children was similar to that
observed in adult patients [97]. Gojo et al. reported a phase I trial using entinostat in
adults with refractory and relapsed acute leukemias.

In this study, entinostat

effectively inhibited HDAC activity, induced p21 expression, histone acetylation and
caspase-3 activation in bone marrow cells [98].

In summary, these studies

demonstrate HDACi to be promising for the treatment of hematological malignancies.
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In addition to hematological malignancies, several clinical trials have been
conducted to test these agents in patients with glioblastoma, ovarian, breast,
colorectal and lung cancer [99-101].

In contrast to patients with hematological

malignancies, these trials resulted in moderate or no effect. Possible explanation for
the efficacy differences between liquid and solid tumors include the inability to achive
appropriate doses of HDACi and consistent acetylation of target proteins. In clinical
trials vorinostat’s half-life is relatively short, 91.6 to 127 minutes administrated orally
and 34.7 to 42.4 minutes administrated intravenously [102, 103]. These data suggest
that continuous administration of this agent may be necessary to achieve clinical
response.
While vorinostat has been approved as a single agent for the treatment of
cancer, several preclinical and clinical studies have demonstrated that HDACi work
better in combination with other anticancer agents [104]. HDACi have been combined
with conventional cytotoxic therapies like DNA-damaging and targeted therapies like
proteasome inhibitors and hypomethylating agents [105-107]. These combinations
produced enhanced apoptosis in different malignant cell lines. Several clinical trials
are

presently

being

conducted

using

HDACi

in

combination

with

other

chemotherapies; however, the mechanism of action of these combinatorial treatments
is not well understood.
As mentioned before, HDACi have been shown to induce oxidative stress in
different cancer cells. Knowing that cancer cells have higher levels of ROS compared
to normal cells, this difference can be used as a therapeutic strategy to treat cancer.
Combining HDACi with agents that cause further oxidative stress might enhance the
efficacy of HDACi for the treatment of cancer.
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Different studies combining HDACi with other chemotherapies have shown to induce
oxidative stress, however the mechanism by which these combination induce oxidative
stress is not very well understood. Rosato RR, et al. reported that the HDACi LAQ824 in combination with fludarabine synergistically increased ROS levels in ALL cells.
This increase in ROS resulted in DNA damage [108].

Oxidative stress is also a

marker for the synergy observed between entinostat and the chemotherapeutic agent
5-azacytidine in AML and ALL cells [109]. PEITC is another compound that induce
oxidative stress and has been combined with HDACi. In this study, depletion of GSH
by PEITC increases sensitivity to vorinostat in leukemia cells [110]. Furthermore, the
combination of HDACi with PEITC also induced ROS accumulation and apoptosis in a
vorinostat-resistant cell line via activation of the NADPH oxidase. Induction of ROS by
this combination allows for the translocation of the transcription factor Nrf2 to the
nucleus, stimulating transcription of genes involved in the GSH system [110].

29

1.4

Adaphostin as a ROS generating agent
Adaphostin has been identified as a potential anticancer agent to treat acute

leukemias such as ALL and AML. This molecule is a second-generation tyrphostin
kinase inhibitor, which mimics tyrosine binding to kinases [111]. While this agent was
developed as a BCR/ABL kinase inhibitor, subsequent studies have demonstrated that
adaphostin’s antileukemic activity is not selective for the presence of Bcr/Abl kinase
[112].

Importantly, adaphostin demonstrates selectivity for leukemia cells as

compared to normal lymphocytes [113]. Subsequent studies have been devoted to
understanding the mechanism of action of this drug.

Figure 10. Chemical structure of adaphostin. Adaphostin is a
second-generation tyrphostin kinase inhibitor. www.trc-canada.com

Mechanistic studies have demonstrated that adaphostin increases levels of
intracellular ROS by the depletion of GSH, resulting in DNA damage and induction of
apoptosis in leukemia cells [113]. More detailed investigations have explained the
induction of oxidative stress by adaphostin. Le, S.B. et al reported that the increase in
ROS in cells treated with adaphostin is the result of an accumulation in the
mitochondria, where adaphostin binds to complex III, inhibiting electron transport
[114]. Moreover, transcriptional and proteomic analyses of adaphostin-treated cells
demonstrated an upregulation of oxidative stress-related genes [115, 116].
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Hose, C. et al. performed a transcriptional profile in three different leukemia cells lines
(Jurkat, K562 and HL60) treated with 1 and 10 µM of adaphostin for 2 to 6 hours. The
results demonstrated that adaphostin cytotoxicity in these cells is caused by the
release of free iron resulting in redox alteration and cell death [115]. In a second
study, proteomic analyses performed in myeloid leukemia cells treated with increasing
concentrations of adaphostin resulted in upregulation of oxidative stress related
proteins such as heat shock proteins, glutathione s-transferase, and superoxide
dismutase [116].

Furthermore, studies in glioblastoma cells treated with adaphostin

indicate that the antioxidant heme oxygenase-1 is upregulated [117].
Combinatory studies also have demonstrated the importance of ROS in the
cytotoxic effect of adaphostin. A panel of leukemia cells was treated with adaphostin
in combination with the proteasome inhibitor bortezomib, resulting in synergistic
induction of apoptosis.

This synergy was associated to elevated levels of ROS,

downregulation of the Raf/MEK/ERK pathway and JNK activation. All these events
were attenuated when cells were treated with the antioxidant NAC, demonstrating that
oxidative stress plays an important role in the synergistic mechanism [118].

This

combination was also tested in BCR/ABL positive cells resistant to imatinib resulting in
synergistic induction of apoptosis in which potentiation of ROS was observed. Again,
NAC blocked the synergistic effect implicating oxidative stress as a mechanism by
which this combination overcomes imatinib resistance [118]. Taken together, these
observations indicate that adaphostin is a redox-modulatory agent.
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Two different studies of adaphostin’s effect in vivo have been reported. One
study showed that adaphostin increased survival in an orthotopic glioblastoma mouse
model [119].

The second study, a report on the pharmacokinetics of adaphostin,

showed that adaphostin was stable in human plasma [120]. Collectively, this data
points to adaphostin as a good candidate to study in combination with HDACi.

1.5

Study Rationale, Hypothesis and Specific Aims
Despite advances in the treatment of pediatric leukemia, 20% of children die

due to relapsed or refractory disease. Furthermore, survivors have an increased risk of
death compared to age matched cohorts due to late effects of their therapy.
Identification and development of new therapeutic strategies with specific and
selective antileukemia activity are of utmost importance for these patients. Histone
deacetylase inhibitors (HDACi), have shown to be effective in the treatment of
hematological malignancies. The major accepted mechanism of action for these drugs
is through hyperacetylation of histones. Interestingly, several studies have indicated
that HDACi cause oxidative stress, which contributes to the cytotoxicity of these drugs
[87]. Combining agents that cause further oxidative stress might enhance the efficacy
of HDACi for the treatment of leukemia. The tyrphostin inhibitor adaphostin is one such
agent. Adaphostin was originally identified as a tyrosine kinase inhibitor, but
subsequent studies defined oxidative stress as its primary mechanism of action.
Furthermore, adaphostin demonstrates selectivity for leukemia cells as compared to
normal lymphocytes [113]. The present study investigates the efficacy and the redox
mechanism of HDACi in combination with adaphostin in leukemia models.
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The hypothesis for this study is that HDACi in combination with adaphostin
will synergize, causing oxidative stress and cell death through the activation of
the apoptotic mitochondrial pathway.
To test this hypothesis the following specific aims were conducted:
•

Specific Aim 1: To determine the mechanism by which HDACi and adaphostin
synergize to induce apoptosis.

•

Specific Aim 2: To determine how ROS is generated by the combination and
its role in the induction of apoptosis.

•

Specific Aim 3:

To determine how specific HDACi alter the oxidative

environment to promote cell death.
Understanding the mechanism involved in the synergy between HDACi and
adaphostin will advance scientific knowledge of how the action of HDACi could be
augmented in leukemia models. Moreover, this information could be used for the
development of effective clinical trials combining HDACi with other anticancer agents.
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CHAPTER 2: MATERIALS AND METHODS
2.1

Cell lines
Jurkat and Molt-4 cells, representative of human T-acute lymphocytic leukemia

(T-ALL) and I9.2 (caspase-8 deficient Jurkat cells) were acquired from American Type
Culture Collection (ATCC; Manassas, VA). All cell lines were validated by short
tandem repeats (STR) DNA fingerprinting by the MD Anderson characterized cell line
core (CCSG) laboratory. All cells were grown in a humidified incubator with 5% CO2 at
37o C. Jurkat and Molt-4 were cultured in RPMI 1640 with 10% (Jurkat) or 20% (Molt4) (v/v) heat-inactivation fetal bovine serum (FBS; Hyclone, Logan, UT), 2 mM Lglutamine, 100 U/mL penicillin, and 100 g/mL streptomycin (Sigma St. Louis, MO).
I9.2 cells were cultured in RPMI 1640 with HEPES (N-2-hydroxyethylpiperazine-N-2ethanesulfonic),

sodium

pyruvate

and

L-glutamine

(ATCC;

Manassas,

VA)

supplemented with 15% FBS and 100 U/mL penicillin, and 100 g/mL streptomycin
(Sigma St. Louis, MO).

2.2

Chemicals and antibodies
Adaphostin was provided by the NCI/NIH Developmental Therapeutics Program

(Bethesda, MD). Vorinostat was purchased from Cayman Chemicals (Ann Arbor, MI)
and entinostat was provided by Syndax (Waltham, MA). Propidium iodide (PI), NAcetyl-L-cysteine (NAC), thioredoxin reductase from rat liver, NADPH and insulin from
bovine pancreas were purchased from Sigma (St. Louis, MO). Dye for the detection of
intracellular superoxide (dihydroethium - HE) was purchased from Invitrogen (Grand
Island, NY). Tetramethylrhodamine ethyl ester (TMRE) was purchased from Molecular
Probes (Eugene, OR). Caspase-3 substrate, DEVD-amc and the caspase inhibitors
zVAD-fmk, DEVD-fmk, LEHD-fmk and IETD-fmk were purchased from Enzo Life
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Sciences (Farmingdale, NY). Antibodies were purchased for polyclonal anti-acetylhistone H3 and anti-histone H3 (Abcam, Inc., Cambridge, MA), monoclonal antithioredoxin (BD Biosciences Pharmigen, San Diego, CA) and anti-acetylated lysine
(Cell Signaling, Danvers, MA).

2.3

DNA fragmentation and synergy analysis
Sub-diploid population was measured as an indicator of apoptosis using

propidium iodide (PI) staining followed by flow cytometric analysis.

After 24 h of

incubation with desired treatment, cells were centrifuged, washed with PBS and
suspended in 500 µL of PI solution (50 g/mL PI, 0.1 % Triton X-100, and 0.1%
sodium citrate in PBS) for a minimum of 3 h. Samples were assessed by flow
cytometry on the FL-3 channel (FACSCalibur, Becton, Dickinson, Franklin Lakes NJ).
CellQuest software (BD Bioscience, Franklin Lakes NJ) was used for analysis of the
data. After three different experiments, synergy was calculated using isobologram
analysis based on the Chou and Talalay method [121] with Calcusyn software (Biosoft,
Ferguson, MO).

2.4

Detection of changes in mitochondrial membrane potential
Changes

in

mitochondrial

membrane

potential

were

measured

using

tetramethylrhodamine ethyl ester (TMRE) staining. TMRE is a cell permeable dye with
positive charge, which is reduced by the interaction with active positively charged
mitochondria. Increase in reduced TMRE is indicative of changes in mitochondrial
membrane potential.

After treatment with synergistic concentrations, cells were

centrifuged, washed with PBS, and incubated with 25 nM TMRE in 10 mM HEPES,
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150 mM NaCl, 5 mM KCl, 1 mM MgCl, and 1.8 mM CaCl, pH 7.4 in a volume of 1 mL
for 30 min at 37°C in the dark. After 30 min, cells were washed in PBS and
fluorescence intensity was analyzed by flow cytometry on the FL-2 channel and
analyzed by CellQuest software.

2.5

Detection of intracellular superoxide
The intracellular superoxide level was measured using the cell-permeable

dihydroethidium (HE) dye followed by flow cytometry analysis. Briefly, cells were
centrifuged and suspended in 1 mL of PBS containing 330 nM HE. The samples were
incubated for 30 min in the dark at 37o C. Cells were centrifuged and washed with
PBS and re-suspended in 500 µl of PBS. Fluorescence intensity was assessed by flow
cytometer on the FL-3 channel and analyzed by CellQuest software.

2.6

Caspase-3-like activity assay
After treatment with the synergistic concentrations, cells were centrifuged,

washed, then suspended in 150 µl PBS and lysed by freezing and thawing once on dry
ice. Triplicates of 50 µl of lysate were loaded in a 96-well plate and 150µl of 50 M
DEVD-amc in DEVD buffer (10% sucrose, 0.001% IGEPAL, 0.1% CHAPS, 5 mM
HEPES, pH 7.25) were added to each well. The release of fluorescence (amc)
generated from the cleavage of DEVD-amc was measured using a spectrofluorometer
(SpectraMax Gemini EM, Molecular Devices, Sunnyvale, CA) with an excitation of 355
nm and emission of 460 nm.
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2.7

Acid extraction of histones
Purification of histones was performed as described previously [122]. Briefly,

after drug treatment, cells were harvested and nuclei were isolated by lysis of cells in a
hypotonic buffer containing 10 mM Tris-HCl, pH 8.0, 1 mM KCl, 1.5 mM MgCl2, 1 mM
DTT. Protease and phosphatase inhibitors at a final concentration of 1 mM were
added immediately prior to lysis. Lysates were rotated for 30 min at 4°C, and then
centrifuged for 10 min at 10,000 rpm at 4°C. Supernatant was removed and isolated
nuclei were suspended in 400 µl of 0.4 N H2SO4 and rotated for 30 min or overnight at
4°C. Nuclei lysates were centrifuged for 10 min at 12,500 rpm at 4°C to remove the
nuclear debris. Supernatant was transferred to a new eppendorf tube and 132 µl of
trichloroacetic acid (TCA) was added and incubated on ice for 30 min, then centrifuged
for 10 min at 12,500 rpm at 4°C. Supernatant was removed and the histone pellet was
washed with ice-cold acetone and centrifuged for 5 min at 12,500 rpm at 4°C. Finally
the acetone was removed and histone pellets were dissolved in 100 µl of sterile water.

2.8

Immunoprecipitation
After treatment, cells were resuspended in lysis buffer (1% Triton X-100, 150

mM NaCl, 5 mM EDTA, 20 mM sodium phosphate, pH 7.4). Aliquots of protein lysates
(1000 µg) were immunoprecipitated overnight with 1 µg/mL of Trx antibody. Protein G
agarose beads were added to each sample and rotated for a minimum of 2 h, then
washed with lysis buffer and centrifuged three times.

Samples were loaded onto a

15% sodium dodecyl sulfate (SDS)-polyacrylamide gel, transferred to nitrocellulose
membrane, and blocked for 1 h with 5% nonfat dry milk in Tris-Buffered Saline Tween20 (TBS-T) (0.05% Tween-20). Membranes were probed overnight at 4oC with 1:1000
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dilution of primary antibody (acetylated-lysine) in 5% milk in TBS-T. The bound
antibodies were detected using enhanced chemiluminescence, ECL plus Western
blotting detection system (Amersham Bioscience, UK limited, Little Chalfont
Buckinghamshire, England).

2.9

Quantification of cellular glutathione (GSH) levels
After 24 h of treatment, cells were harvested and equal numbers of cells were

aliquoted to new tubes and 50 µM of monochlorobimane (mBCL) was added to each
sample, except for the unstained control. mBCL is a cell permeable probe, which
react with the thiol groups in GSH resulting in release of a fluorescent signal. Cells
were incubated with the mBCL for 15 minutes at 37°C. After incubation, the reaction
was stopped by adding trichloroacetic acid to a final concentration of 5%. Samples
were collected and an equal volume of methylene chloride was added, followed by
centrifugation at 3500 RPM for 2 minutes. After centrifugation, 200 µl from the
aqueous phase was collected in a well of a white opaque 96 well plate. Fluorescence
was measured using a microplate reader (Spectra Gemini EM, Molecular Devices, Inc.
Sunnyvale CA) with excitation 398 nm and emission of 488 nm. GSH level was
calculated using a standard curve with increasing GSH concentration that was
prepared in parallel with the samples.

2.10

Thioredoxin Activity
Trx activity was determined using a spectrophotometric end-point insulin assay,

where insulin is used as a substrate to measure the thiol formation in the reaction
[123].

Briefly, after treatment with the synergistic concentrations, cells were

centrifuged, washed with PBS and homogenized in cold buffer (50 mM potassium
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phosphate, pH 7.4, containing 1 mM EDTA) followed by three cycles of freezing and
thaws.

Thirty µg of sample protein were incubated with 85 mM HEPES, 0.3 mM

insulin, 660 µM NADPH, 3 mM EDTA and 0.1 unit of Trx reductase (TrxR) at 37°C for
60 min. After incubation, the reaction was stopped by adding 500 µl of 6 M guanidine
hydrochloride with 4 mg/mL of 5,5′-dithio-bis (2-nitrobenzioic acid). Absorbance at 412
nm was measured using a SpectraMax Gemini EM spectrophotometer. For each
sample, a blank containing all reagents, except TrxR, was used, and absorbance of
the blank was subtracted from that of the sample with TrxR.

2.11

Oxidative stress and antioxidant defense PCR array
Total RNA was isolated from cells using the RNeasy Mini Kit (Qiagen, Valencia,

MA). The concentration and quality of the RNA were measured using a NanoDrop
ND-1000 Spectrophotometer (Thermo Scientific Inc., Walthaman, MA).

For each

sample, 0.5 µg of RNA was used to synthesize cDNA using the RT2 First Strand Kit
(Qiagen, Valencia, MA).

Real-time PCR was performed according to the

manufacturer’s protocol conditions (Qiagen, Valencia, MA).

2.12

In vivo experiments
Female NOD/SCID, NOD-SCID-IL-2gnull and NOD-Cg-Rag1 mice purchased

from the National Cancer Institute (Bethesda, MD) were used. All animals used for in
vivo experiments were housed in standard cages, at three to four mice per cage and
provided with food and water. Animal experiments were performed in accordance with
the MD Anderson Institutional Animal Care and Use Committee and approved by the
American Association for Laboratory Animal Science (AALAS). Mice were injected
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intravenously (IV) with 1x105 Molt-4 cells (representative of T-ALL). One week after
cell injection, mice bearing leukemia cells were divided into four groups (3 mice per
each group). Each mouse was injected intraperitoneally (IP) with vehicle, single drugs
alone or drugs in combination.

Dosing was done thrice weekly.

To determine

treatment efficacy, we conducted complete blood cell counts using approximately 25 µl
of mouse blood on a weekly basis. Lymphocytes were isolated adding 1 mL of ACK
(Ammoniun-Chloride-Potassium) lysing buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM
EDTA) to blood. Then samples were mixed followed by centrifugation at 12,000 RPM
for 3 minutes. After centrifugation, supernatant was carefully aspirated and cell pellet
was suspended in 50 µl of PBS. Isolated lymphocytes from mice were stained using
10 µl APC anti-human CD45 antibody (Biolegend Inc. San Diego, CA) in 50 µl of PBS
containing cells, followed by flow cytometery and analysis using CellQuest software.

2.13

Statistical analysis
For each condition, at least three experiments were performed, and the results

are presented as the mean ± standard deviation (SD). Statistical differences between
conditions were analyzed using independent, two-tailed t-tests (Microsoft Excel
software, Redmond, WA).

A p-value < 0.05 was considered to be statistically

significant. To determine synergy, Calcusyn software (Biosoft, Ferguson, MO) was
used to calculate combination index (CI) values with isobologram analysis using the
Chou and Talalay method [121]. A CI value less than 1.0 indicates synergy, equal to
1.0 indicates an additive effect and more than 1.0 represents an antagonist interaction.
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CHAPTER 3: RESULTS
3.1

HDACi (vorinostat and entinostat) synergize with adaphostin to induce

DNA fragmentation in ALL cells.
Previous studies have demonstrated that HDACi work better in combination
than as a single agent in different types of cancer including hematological
malignancies. In addition, data suggests that one mechanism of action for HDACi is
through the induction of oxidative stress. To test if combining HDACi with a ROS
generating agent would augment HDACi efficacy, we treated two different types of ALL
cell lines with HDACi and adaphostin (a ROS generating agent). Jurkat and Molt-4
cells were treated with a range of HDACi (vorinostat or entinostat) and adaphostin
concentrations (100 nM – 2.5 µM), incubated for 24 h and DNA fragmentation was
determined by flow cytometry. Figure 11 shows an increase in DNA fragmentation
when Jurkat and Molt-4 cells were treated with increasing concentrations of the single
agents. DNA fragmentation was significantly enhanced in Jurkat cells when treated
with increased concentrations of adaphostin (0.5 and 0.75 µM) with 0.75 µM of
vorinostat (63.5% and 71.8%, respectively; p < 0.05) or adaphostin (0.5, 0.6 and 0.75
µM) with 2.5 µM of entinostat (68.3%, 78.7 and 83.6%, respectively; p < 0.05). In
Molt-4 cells, a significant increase in DNA fragmentation was observed when 1.5 or
2.5 µM adaphostin was combined with 1.5 µM vorinostat (70.5% and 78.3%,
respectively; p < 0.05) or 2.5 µM adaphostin with 2.5 µM of entinostat (76.3%; p <
0.05).
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Figure 11. Combination of HDACi (vorinostat or entinostat) with
adaphostin induces DNA fragmentation. 5 x 105 Jurkat cells (left
panel) and Molt-4 cells (right panel) were treated with increasing
concentrations (0.1-2.5 µM) of adaphostin (Ada), vorinostat (Vori),
entinostat (Enti) or the combination of Ada-Vori or Ada-Enti for 24 h.
(Drug concentration for Jurkat cells were 0.25, 0.5 and 0.75 µM Ada or
Vori; 1, 1.5 and 2.5 µM Enti. For Molt-4 0.75, 1.5 and 2.5 µM Ada; 0.5,
0.75 and 1.5 µM Vori; 0.75, 1.5 and 2.5 µM Enti). DNA fragmentation
(% Subdiploid) was assessed by PI staining following flow cytometry.
Error bars represent the means ± S.D. of three independent
experiments. *p < 0.05 as compared with either ada, vori or enti
treatment alone.
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Synergy analysis using the Chou and Talalay method [121], demonstrates that
adaphostin synergizes with both vorinostat or entinostat in Jurkat and Molt-4 cells. A
combination index (CI) value less than 1.0 indicates synergism whereas a CI value
equal to 1.0 or more than 1.0 indicates an additive or antagonist interaction
respectively. Representations of different synergistic combinations are presented in
Figure 12.

Figure 12. HDACi (vorinostat or entinostat), synergize with
adaphostin to induce DNA fragmentation. Synergy was calculated
using isobologram analysis. A combination index (CI) value < 1.0
indicates synergism. Tables display some of the synergistic
combinations in Jurkat and Molt-4 as indicated by the CI values.
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To test if the combination of HDACi and adaphostin has any toxic effects in
normal cells, peripheral blood mononuclear cells (PBMC) from healthy donors were
isolated and treated with the synergistic combinations of 0.5 µM adaphostin plus 0.5
µM vorinostat or 0.75 µM adaphostin plus 2.5 µM entinostat. Cells were harvested
after 24 h of incubation and cell viability was measured by trypan blue exclusion.
Figure 13 shows that neither combination affected the viability of PBMC (Figure 13).
In contrast, Jurkat cells treated with both combinations show a decrease in cell viability
demonstrating specificity for leukemic cells.

Figure 13. The combination of HDACi and adaphostin do not affect
the cell viability of healthy peripheral blood mononuclear cells
(PBMC). 5 x 105 PBMC or Jurkat cells were treated with 0.75 µM Ada,
0.5 µM Vori, 2.5 µM Enti and the synergistic combinations of 0.5 µM Ada
plus 0.5 µM Vori or 0.75 µM Ada plus 2.5 µM Enti. After 24 h treatment,
cell viability was measured by trypan blue exclusion. Error bars represent
the means ± S.D. of three independent experiments.
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To elucidate the mechanism of synergy, the subsequent experiments were
performed in Jurkat cells with specific synergistic drug concentrations. The synergistic
concentrations were selected based on the CI values (Figure 12). We decided to
select two combinations that resulted in the low CI value of 0.6. These combinations
were 0.5 µM of adaphostin in combination with 0.5 µM of vorinostat and 0.75 µM of
adaphostin with 2.5 µM entinostat.
Since HDACi alone are known to induce acetylation of histones, we tested
whether the synergistic combinations have any further effect on the acetylation of
histones. Jurkat cells were treated with the synergistic combinations of adaphostin
plus vorinostat or adaphostin plus entinostat and harvested at 24 h. Acid extraction of
histones was performed and levels of total and acetylated histone H3 were measured
by Western blot. As expected, increases in acetylation of histone H3 were observed in
cells treated with either HDACi (vorinostat or entinostat). However, no further changes
in acetylation were observed with either of the synergistic combinations (Figure 14).

Figure 14. Synergistic combinations do not affect the
acetylation of histone H3 induced by HDACi. 5 x 106 Jurkat
cells were treated with the synergistic combinations of 0.5 µM
Ada and 0.5 µM Vori or 0.75 µM Ada and 2.5 µM Enti. After 24
h of incubation cells were harvested and acid extraction of
histones was performed. Acetylated histone H3 and total
histone H3 were measured by Western blot.
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3.2

Induction of DNA fragmentation by HDACi and adaphostin is caspase-

dependent.
Previous results demonstrate that the combination of HDACi and vorinostat
synergize to induce DNA fragmentation in ALL cells. Since DNA fragmentation is a
hallmark of apoptosis, we next investigated if a caspase-dependent apoptotic pathway
was activated. In order to test if caspase-3 is activated and specifically at what time it
is activated, we measured caspase-3-like activity in cells treated with the drug
combinations at different time points. Jurkat cells were treated with the synergistic
combinations of adaphostin plus vorinostat or adaphostin plus entinostat and
harvested at different time points (2, 4, 8, 12, 16 and 24 h). Caspase-3-like activity
was measured using DEVD-amc as a substrate. Cleavage of this substrate by
caspase-3 liberates amc, creating a fluorescent signal, which was read on a
spectrofluorometer. Figure 15 shows that both combinations increased caspase-3-like
activity in a time dependent manner. Significant changes were observed at 12 h when
compared to control (p-value < 0.05).
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Figure 15. The combination of HDACi and adaphostin induce
caspase-3 activation in a time dependent manner. 2 x 106 Jurkat
cells were treated with the synergistic combinations of 0.5 µM Ada
and 0.5 µM Vori or 0.75 µM Ada and 2.5 µM Enti. Caspase-3 activity
was assessed by measuring the fluorescent intensity released from
the cleavage of the fluorogenic substrate DEVD-amc at different time
points (2 – 24 h). Error bars represent the means ± S.D. of two
independent experiments. *p < 0.05 as compared with control or
either agent alone.

To validate the previous results and to determine which specific apoptotic
pathway is activated, cells were pre-treated with either 20 µM zVAD-fmk (pan caspase
inhibitor), 25 µM IETD-fmk (caspase-8 inhibitor), 25 µM LEHD-fmk (caspase-9
inhibitor) or 25 µM DEVD-fmk (caspase-3 inhibitor) for 30 min and then treated with
the synergistic concentrations of HDACi and adaphostin for 24 h. After 24 h, the cells
were stained with PI and DNA fragmentation was measured by flow cytometry. As
shown in Figure 16, apoptotic DNA fragmentation induced by the combinations was
significantly reduced when caspase-8, -9 or -3 activity was blocked (p-value < 0.05).
Comparing the fold changes in DNA fragmentation using each inhibitor, the caspase-9
inhibitor confers the stronger effect (7 fold change for ada-vori or 11 fold change for
ada-enti) when compared to caspase-8 (3 fold change for ada-vori or 2 fold change for
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ada-enti) or caspase-3 (3 fold change for ada-vori or 5 fold change for ada-enti)
inhibitors.

Figure 16. Induction of DNA fragmentation by HDACi and
adaphostin synergy is caspase dependent. 5 x 105 Jurkat
cells were pre-treated with either 20 µM pan-caspase, 25 µM
caspase-3, caspase-8 or caspase-9 inhibitors for 30 min. After
pre-treatment, the samples were treated with 0.5 µM Ada and
0.5 µM Vori or 0.75 µM Ada and 2.5 µM Enti for 24 h and dyed
with PI. DNA fragmentation was assessed by flow cytometer.
Error bars represent the means ± S.D. of three independent
experiments. *p < 0.05 as compared with no inhibitor.
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To better understand the role of caspase-8 in the induction of DNA
fragmentation by the synergistic combinations, Jurkat variants that were caspase-8
deficient (I9.2 cells) were used. Parental Jurkat and I9.2 cells were treated with both
synergistic combinations for 24 h.

DNA fragmentation was measured by flow

cytometry using PI staining. In both combinations, cells that lacked caspase-8 showed
a moderate decrease in DNA fragmentation when compared to parental Jurkat cells
(Figure 17 A-B). These data suggest that caspase-8 is not the principal caspase
involved in the synergy between HDACi and adaphostin.

Figure 17. Caspase-8 is not required for the induction of DNA
fragmentation by the combination of HDACi and adaphostin.
5 x 105 cells, either I9.2 (caspase-8 deficient) or parental Jurkat
cells were treated with the synergistic combinations of 0.5 µM Ada
and 0.5 µM Vori or 0.75 µM Ada and 2.5 µM Enti for 24 h. DNA
fragmentation was measured by PI staining in cells treated with
the synergistic concentration of A) Ada-Vori and B) Ada-Enti. Error
bars represent the means ± S.D. of three independent
experiments.
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3.3

The combination of HDACi and adaphostin disrupts the mitochondrial

membrane potential and potentiates superoxide levels.
Previous data generated using caspase inhibitors and caspase-8 deficient cells
suggest that caspase-9 mediates the induction of apoptosis in cells treated with the
combination of HDACi and adaphostin. Since caspase-9 can be activated by both
apoptotic pathways (extrinsic and intrinsic), we tested if these drug combinations have
any effect on the mitochondrial membrane potential. To determine if mitochondrial
membrane potential is affected and specifically at what time this event occurs, Jurkat
cells were treated with both combinations and harvested at different time points (2, 4,
8, 12, 16 and 24 h). Changes in mitochondrial membrane potential were measured by
flow cytometry using TMRE staining.

Significant loss of membrane potential was

detected at 12 h and sustained through 24 h in both combinations (Figure 18 A-B).

Figure 18. Combination of HDACi and adaphostin disrupts
mitochondrial membrane potential starting at 12 h. 5 x 105
Jurkat cells were treated with the synergistic combinations of 0.5
µM Ada and 0.5 µM Vori or 0.75 µM Ada and 2.5 µM Enti. After
treatment changes in mitochondrial membrane potential was
measured by TMRE staining in A) Ada-Vori or B) Ada-Enti
combinations at different time points (2-24 h). *p < 0.05 as
compared with control.
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To elucidate whether the loss of mitochondrial membrane potential precedes or
follows caspase activation, cells were pre-treated with the pan-caspase inhibitor ZVAD
followed by treatment with the synergistic concentrations.

After 24 h, cells were

harvested and mitochondrial membrane potential was measured. Figure 19 shows
that ZVAD blocked the loss of membrane potential caused by both combinations.
These results suggest that caspase activation is downstream of the changes in
mitochondrial membrane potential.

Figure 19. Caspase activation is downstream of loss of
mitochondrial membrane potential. 5 x 105 Jurkat cells were
pre-treated with 20 µM pan-caspase inhibitor for 30 min. After
pre-treatment cells were treated with the synergistic
combinations of 0.5 µM Ada and 0.5 µM Vori or 0.75 µM Ada
and 2.5 µM Enti. After 24 h mitochondrial membrane potential
was measured by TMRE staining. Error bars represent the
means ± S.D. of three independent experiments.
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Increased endogenous levels of ROS can promote mitochondrial membrane
permeabilization resulting in the release of cytochrome c and activation of caspase-9.
Since decreased mitochondrial membrane potential has been shown to promote an
environment of oxidative stress, we sought to determine whether there was an
increase in superoxide levels and, if so, at what specific time point these are
generated. Cells were treated with the combinations and harvested at different time
points (2, 4, 8, 12, 16 and 24 h) and superoxide levels were measured using HE
staining. Results show that both combinations potentiate superoxide levels more than
the single agents.

Significant increases were observed at 16 h and continued

increasing through 24 h (Figure 20 A-B). Based on the time course experiments,
these results place the induction of oxidative stress downstream of the initial loss of
mitochondrial membrane potential that started at 12 h.

Figure 20. HDACi and adaphostin potentiate superoxide levels in a
time dependent manner. 5 x 105 Jurkat cells were treated with the
synergistic combinations of 0.5 µM Ada and 0.5 µM Vori or 0.75 µM Ada
and 2.5 µM Enti. Superoxide levels were measured by HE staining in
cells treated with the synergistic concentrations of A) Ada-Vori and B)
Ada-Enti at different time points (2-24 h). Error bars represent the means
± S.D. of three independent experiments. *p < 0.05 as compared with
control.
52

3.4

NAC blocks DNA fragmentation in cells treated with adaphostin and

vorinostat, but not in cells treated with adaphostin and entinostat.
Previous results suggest that oxidative stress might play an important role in the
mechanism of synergy between HDACi (vorinostat and entinostat) and adaphostin. In
order to elucidate if ROS contributes to cell death, we used NAC as an antioxidant.
Cells were pre-treated with 24 mM NAC for 30 min. Then cells were treated with the
drug combinations.

After 24 h of treatment superoxide levels, changes in the

mitochondrial membrane potential, DNA fragmentation and caspase-3 activity were
measured as previously described.

As expected, NAC decreased the levels of

superoxide in both combinations, demonstrating that NAC is blocking oxidative stress
(Figure 21A).

In addition, NAC was able to reverse the loss of mitochondrial

membrane potential in both combinations, suggesting that production of oxidative
stress precedes the loss of mitochondrial membrane potential (Figure 21B). Finally, to
investigate the role of superoxide production in cell death, we measured DNA
fragmentation and caspase-3 activity in cells pre-treated with NAC and then with the
drug combinations. DNA fragmentation was decreased by NAC in cells treated with
adaphostin plus vorinostat, but not in cells treated with adaphostin plus entinostat
(Figure 21C).

These results were confirmed when caspase-3 activation was

measured in cells pre-treated with NAC followed by the drug combinations (Figure
21D). All together, these results suggest that at the synergistic concentrations, the
combination of adaphostin plus vorinostat might have a different mechanism of
inducing oxidative stress mediated-apoptosis compared to the combination of
adaphostin plus entinostat.
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Figure 21. Superoxide levels precede the loss of mitochondrial
membrane potential and NAC blocks cell death in cells treated
with Ada-Vori but not Ada-Enti. Jurkat cells were pretreated with 24
mM NAC for 30 min, then treated with the synergistic combinations of
0.5 µM Ada and 0.5 µM Vori or 0.75 µM Ada and 2.5 µM Enti. After 24
h treatment, 5 x 105 cells were harvested to measure A) Superoxide
levels, B) Mitochondrial membrane potential, C) DNA fragmentation and
2 x 106 cells were harvested to measure D) Caspase-3-like activity.
Error bars represent the means ± S.D. of three independent
experiments. *p < 0.05 as compared with no NAC.
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3.5

Glutathione (GSH) & thioredoxin (Trx) are not affected by the synergistic

combination of adaphostin and HDACi.
In order to elucidate the main differences between these two combinations we
first assessed the involvement of GSH in the mechanism of synergy.

GSH were

measured in cells treated with the drug combinations. After 24 h of treatment, cells
were harvested and GSH levels were measured using monochlorobromane as a
substrate, which react with the thiol groups in GSH resulting in release of a fluorescent
signal.

Results show a two-fold decrease in GSH levels in cells treated with

adaphostin and entinostat, and one-fold decrease in cells treated with adaphostin and
vorinostat (Figure 22).

Figure 22. Glutathione (GSH) levels in cells treated with
HDACi and adaphostin. 1 x 106 Jurkat cells were treated with
the synergistic combinations of 0.5 µM Ada and 0.5 µM Vori or
0.75 µM Ada and 2.5 µM Enti. After 24 h treatment, GSH levels
were measured using monochlorobimane as a substrate. Error
bars represent the means ± S.D. of three independent
experiments.
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Since NAC not only alters the levels of GSH, but any cysteine-containing
molecule, and to better elucidate the role of GSH in this mechanism, we used
glutathione ethyl ester (GSHee) to directly address a role for GSH.

GSHee is a

soluble molecule, which enters in the cell and undergoes hydrolysis by intracellular
esterases to be converted to GSH. Therefore, treatment with GSHee is commonly
used to increase levels of GSH within the cells.
As expected, increases in GSH levels were observed in cells pre-treated with
GSHee (Figure 23A). However GSHee did not block the previously observed loss of
mitochondrial membrane potential or DNA fragmentation (Figure 23B-C).

These

results suggest that changes in GSH levels are not the main mechanism of action for
the generation of oxidative stress in the present model.
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Figure 23. GSHee increases the levels of GSH but does not
block the loss of mitochondrial membrane potential or cell
death in cells treated with HDACi-Adaphostin. Jurkat cells were
pre-treated with 1 mM GSHee for 30 min and then treated with the
synergistic combinations of 0.5 µM Ada and 0.5 µM Vori or 0.75 µM
Ada and 2.5 µM Enti. After 24 h treatment, 1 x 106 cells were
harvested to measure A) GSH levels; and 5 x 105 cells were
harvested to measure B) mitochondrial membrane potential and C)
DNA fragmentation were measured as described previously. Error
bars represent the means ± S.D. of three independent experiments.
*p < 0.05 as compared with no GSHee.
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Thioredoxin (Trx) is another cellular antioxidant and its activity has been
demonstrated to be affected by HDACi. Vorinostat was found to decrease Trx activity
by the upregulation of thioredoxin binding protein 2 (TBP-2) [92]. Furthermore, recent
studies have shown that HDACi can acetylate Trx [62].
acetylation affects Trx activity remains unknown.

However, whether this

We decided to investigate if

acetylation of Trx plays an important role in the synergy between adaphostin and
HDACi. First, we tested if the combination of HDACi and adaphostin induces Trx
acetylation. Figure 18A shows that acetylation of Trx is induced in cells treated with
higher concentrations of vorinostat (5 µM) but not at lower concentrations (0.5 µM
vorinostat).

However, Trx acetylation was observed in cells treated with 2.5 µM

entinostat and this acetylation was further increased by the combination of 0.75 µM
adaphostin and 2.5 µM entinostat (Figure 24A). In order to elucidate if the synergistic
combinations affect Trx activity, we measured Trx activity in cells treated with either
agent alone or in combination.

No changes in Trx activity were observed after

treatment with either of the combinations (Figure 24B).
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Figure 24. The combination of HDACi and adaphostin increases
the acetylation of Trx but does not affect Trx activity. Jurkat cells
were treated with the synergistic combinations of 0.5 µM Ada and 0.5
µM Vori or 0.75 µM Ada and 2.5 µM Enti. After 24 h of incubation 20 x
106 cells were harvested for the immunoprecipitation and 5 x 106 cells
were harvested to measure Trx activity. A) Immunoprecipitation of Trx
was performed and blotted for acetylated Trx. B) Trx activity was
measured using a spectrophotometric end-point insulin assay. Error
bars represent the means ± S.D. of three independent experiments.
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3.6

HDACi and adaphostin combinations induce differential regulation of

oxidative stress related genes.
Previous results demonstrated that NAC blocked the loss of mitochondrial
potential and ROS levels, suggesting that oxidative stress plays an important role in
the synergy between HDACi with adaphostin.

However, NAC blocked DNA

fragmentation in cells treated with adaphostin plus vorinostat but not in cells treated
with adaphostin plus entinostat. To elucidate these differences we investigated the
role of GSH and Trx. Results demonstrated that GSH and Trx are not major players in
these differences. To better understand what factors are involved in the differences
between the two combinations, we examined the expression of different genes
involved in oxidative stress and antioxidant defense. Since we observed changes in
superoxide levels starting at 16 h, we hypothesized that gene changes start earlier.
For that reason, we decided to examine the changes in gene expression at 8 h. RNA
was extracted from cells treated with the synergistic combinations for 8 h. cDNA was
synthesized and a RT2 profile PCR array for genes involved in oxidative stress and
antioxidant defense was performed. Gene regulation was compared between cells not
treated (control) and cells treated with either combination (Ada-Vori or Ada-Enti).
Then these results were compared between each combination.

We selected the

genes with the major fold changes in gene regulation induced by Ada-Vori compared
to Ada-Enti (Table 1). This data shows that genes involved in oxidative stress were
differentially regulated between Ada-Vori and Ada-Enti combinations. In cells treated
with Ada-Enti compared to Ada-Vori, there was up-regulation of aldehyde oxidase 1,
glutathione peroxidase-2, lactoperoxidase, eosinophil peroxidase 2 and scavenger
receptor class A. In cells treated with Ada-Vori compared to Ada-Enti, there were up-
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regulations of glutathione peroxidase 6, peroxiredoxin 6 and down-regulation of
myeloperoxidase and angiopoietin-like 7.

Table 1. Genes involved in oxidative stress are differentially
regulated between Ada-Vori and Ada-Enti combinations. 5 x 106
Jurkat cells were treated with the synergistic combinations of 0.5
µM Ada and 0.5 µM Vori or 0.75 µM Ada and 2.5 µM Enti. After 8 h
cells were harvested and RT2 profile PCR array for genes involved
in oxidative stress and antioxidant defense was performed.
Numbers in red represent a gene up-regulation, numbers in blue
represent a gene down-regulation and number in black represent no
change.
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3.7

In vivo efficacy of HDACi in combination with adaphostin.
Previous results demonstrate that two different HDACi synergize with

adaphostin to induce oxidative stress mediated-apoptosis in vitro. To test if this
combination works in vivo, we used an orthotopic mouse model. Since the U.S. Food
and Drug Administration has not yet approved entinostat, we decided to use vorinostat
for the in vivo experiments. Figure 25 shows the experimental design.

Figure 25. Schematic diagram of in vivo experimental design.
NOD/SCID mice were injected intravenously with leukemia cells and one
week after cell injection, treatment started. Drugs were administrated the
same days thrice weekly. Leukemia burden was monitored weekly by
measuring CD34+ cells present in the blood.
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Twelve NOD-SCID-IL-2gnull mice were injected intravenously (IV) with 1x105
Molt-4 cells (representative of T-ALL). One week after cell injection, mice bearing
leukemia cells were divided into four groups (3 mice per group). We selected the
administration routes and doses based on published data [124, 125]. Each mouse
was injected intraperitoneally (IP) with vehicle, drugs alone or in combination. Group 1
was injected with vehicle (DMSO).
vorinostat.

Group 2 was injected with 125 mg/kg [124]

Group 3 was injected with 50 mg/kg adaphostin [125].

Group 4 was

injected with the drug combination (vorinostat and adaphostin). Drug dosing was done
on the same days thrice weekly.

To determine treatment efficacy we conducted

complete blood cell counts using approximately 25 µl of mouse blood on a weekly
basis. Lymphocytes were isolated using ACK lysing buffer. Isolated lymphocytes
were stained using a fluorescence conjugated antibody (APC anti-human CD45)
followed by flow cytometric analysis.
After the start of drug administration, the mice injected with 50 mg/kg of
adaphostin died unexpectedly on day 11. We observed leukemic cell engraftment at
week 3. One mouse from the group treated with vorinostat died on day 29 and the
rest of the mice died around day 30-33 (Figure 26).
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Figure 26. Molt-4 cells engraftment started at week 3. Twelve
NOD-SCID-IL-2gnull mice were injected intravenous with 1x105
Molt-4 cells. After one week of cell injection, 3 mice per group were
treated thrice weekly with vehicle, 50 mg/kg adaphostin, 125 mg/kg
vorinostat or the combination of adaphostin and vorinostat.
Leukemia burden was monitored by bleeding and isolated
lymphocytes from mouse were stained with anti-human CD45 and
measured by flow cytometry. Each bar represents the average of 3
mice per group or treatment. No bars are presented in the group
treated with adaphostin because mice died during week 1.

Mice treated with 50 mg/kg of adaphostin died during week 1, suggesting
adaphostin toxicity. To find a less toxic dosage, we performed a second pilot by using
NOD-SCID mice, decreasing the drug dosages and changing the treatment schedule.
On this occasion we treated mice with lower doses of each drug daily instead of thrice
a week. Mice were IP injected with 25 mg/kg adaphostin, 50 mg/kg vorinostat or the
combination of vorinostat and adaphostin. After the second week of treatment, we
observed abnormal growth in the abdominal area of mice treated with adaphostin and
the combination. Two mice, one control treated with vehicle and one treated with
adaphostin, were sacrificed and necropsies were performed.
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Necropsies demonstrated gastrointestinal (GI) toxicity in mice treated with adaphostin
(Figure 27). After these findings, we decided to decrease the dose of adaphostin from
25 mg/kg to 12.5 mg/kg.

Figure 27. GI toxicity in mice treated with adaphostin. Necropsy
of mouse treated with either vehicle (DMSO) or 25 mg/kg
adaphostin showed an increase in the size of the GI track in mouse
treated with adaphostin. In contrast mouse treated with vehicle
showed normal GI track.

At week four we did not observe cell engraftment and we injected 5 x 105 Molt-4
cells into each of the remaining mice. We did not observe any cell engraftment at
week 6 (Figure 28) and mice treated with adaphostin and the combination started to
show GI toxicity again at week eight. The treatment was stopped at week nine.
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Figure 28. Molt-4 cell engraftment in NOD-SCID mice. NOD-SCID
mice were injected intravenously with 1x105 Molt-4 cells. After one
week, mice were treated for five days weekly with vehicle, 25 mg/kg
adaphostin, 50 mg/kg vorinostat or the combination of adaphostin and
vorinostat. Leukemia burden was monitored by bleeding and isolated
lymphocytes from mice were stained with anti-human CD45 and
measured by flow cytometry. Each bar represents the average of 3
mice per group or treatment.

Since we observed GI toxicity in mice treated with adaphostin, we decided to
perform toxicity tests to find the appropriate adaphostin dose and treatment schedule.
As presented in table 2, six mice were treated with different doses and schedules. At
week two, one mouse treated with 12.5 mg/kg adaphostin presented with sign of a
tumor in the left leg. We performed a necropsy and we did not find any signs of GI
toxicity or leukemia burden. The remaining mice were treated with their respective
doses for a total of five weeks. After five weeks, no sign of GI toxicity was observed in
any of the mice.
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Table 2. Adaphostin doses and schedule administration. Mice were
injected IP with different doses of adaphostin using different schedules.
After five weeks of treatment, mice were sacrificed and necropsy was
performed.

Based on the toxicity test, we decide to perform a third pilot study. On this
occasion, NOD-Cg-Rag1 mice were injected with 1 x 106 Molt-4 cells per mouse. After
seven days mice were treated with vehicle, 50 mg/kg of vorinostat for 5 days/week,
and/or 8 mg/kg of adaphostin for 3 day/week. After five weeks of treatment we did not
observe GI toxicity, but we didn’t see cell engraftment (Figure 29).

Figure 29. Molt-4 cell engraftment in NOD-Cg-Rag1 mice. NOD-CgRag1 mice were injected intravenously with 1x106 Molt-4 cells. After one
week, mice were treated with vehicle (5 days/week), 8 mg/kg adaphostin
(3 days/week), 50 mg/kg vorinostat (5 days/week) or the combination of
adaphostin and vorinostat. Leukemia burden was monitored by bleeding
and isolated lymphocytes from mouse were stained with anti-human
CD45 and measured by flow cytometry. Each bar represents the
average of 3 mice per group or treatment.
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CHAPTER 4: DISCUSSION
The main objective of this project is to understand how oxidative stress inducing
agents might enhance the efficacy of HDACi for the treatment of ALL. For the first
time, the ROS generating agent adaphostin was used in combination with two different
HDACi (vorinostat and entinostat) in ALL cell lines.

DNA fragmentation and

combination index values demonstrated that HDACi, vorinostat and entinostat,
synergize with adaphostin to induce apoptosis in ALL cells.

Furthermore, the

synergistic concentrations do not affect PBMC from healthy donors, demonstrating
that this effect is selective for ALL cells. This synergy is mainly driven by the activation
of the intrinsic apoptotic pathway, where time course analyses showed that
perturbation of the mitochondrial membrane potential is the earliest event observed.
Following this event, increasing levels of superoxide, caspase activation and ultimately
cell death were observed.

Synergistic apoptosis induction by HDACi and adaphostin.
The observation that HDACi synergizes with adaphostin resulting in apoptosis
is consistent with other studies combining HDACi with different drugs like
topoisomerase inhibitors [126], nucleoside analogs [108], hypomethylating agents
[127], proteasome inhibitors [50, 128] and tyrosine kinase inhibitors [129]. However,
the mechanism by which these combinations induce apoptosis differs between
combinations. These observations can be possibly explained by the pleiotropic effects
of HDACi and the specificity of the cancer cell type. Furthermore, the mechanism of
action of the agent with which the HDACi is combined also plays a role in which
apoptotic mechanisms are activated.
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In the present study, results of experiments using different caspase inhibitors
(pan-caspase, caspase-8, -9, and -3 inhibitors) confirmed that the synergy observed
between HDACi and adaphostin is through the induction of apoptosis. Both caspase-8
and -9 chemical inhibitors reduced DNA fragmentation in cells treated with the
synergistic concentrations of HDACi and adaphostin (Figure 16).

However, the

caspase-9 inhibitor exerted a strong inhibition of cell death in both combinations. In
addition, we found that both combinations induced loss of the mitochondrial membrane
potential (Figure 18). Together, these results suggest that the main mechanism by
which HDACi and adaphostin induce apoptosis is through the intrinsic pathway.
These observations are consistent with other studies where HDACi has activated the
intrinsic pathway in different types of cancer cells [130].
Zhang, et al. examined the effect of the HDACi, suberic bishydroxamate
(SBHA), which is a derivate of vorinostat, in a panel of human melanoma cell lines.
They found that HDACi activated the intrinsic apoptotic pathway. This activation was
attributed to the down-regulation of antiapoptotic proteins XIAP, Bcl-XL and Mcl-1 and
the up-regulation of proapoptotic genes like Bax, Bak and Bim.

These changes

resulted in mitochondrial disruption and consequent activation of caspase-3 [130]. In
contrast to this study, we did not observe changes in the protein levels of XIAP
(Appendix).

This discrepancy can be explained by the use of the combination

vorinostat or entinostat plus adaphostin instead of SBHA alone. Also the cancer type,
since they used melanoma cells instead of leukemia cells might play an important role.
Other studies using vorinostat have also shown activation of the intrinsic
apoptotic pathway by up-regulating Bim in lymphomas [89]. In addition, cleavage of
Bid, perturbation of the mitochondria and release of cytochrome c also has been
reported by others [87, 89]. In a similar way, entinostat induced the activation of the
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intrinsic pathway in lymphoma cells by the down-regulation of Bcl-2 and Bcl-xL
proteins. The combination of entinostat with two different Bcl-2 inhibitors significantly
enhanced this effect [131].

Furthermore, different studies have demonstrated that

overexpression of the Bcl-2 family of proteins can block the cell death induced by
HDACi [85, 132].
HDACi can activate not only the intrinsic apoptotic pathway but also the
extrinsic apoptotic pathway. Nebbioso et al. reported that vorinostat and entinostat
induced the expression of TRAIL in AML cells and in AML blast cells isolated from
patients. The overexpression observed was the result of the activation of the promoter
TNFSF10 [80]. Other studies have demonstrated that HDACi require caspase-8 to
exert their cytotoxic effect, also can enhance the extrinsic pathway signal by
increasing death receptors (DRs) or ligand expression [82, 133, 134].
We observed a decrease in DNA fragmentation with the caspase-8 inhibitor. In
addition, it is well known that activation of caspase-8 can subsequently activate the
intrinsic pathway by the cleavage of Bid. We investigated the role of the extrinsic
pathway in the synergy of HDACi and adaphostin. Pre-treatment with a pan-caspase
inhibitor followed by the synergistic concentrations demonstrated that caspase
activation is downstream of changes in the mitochondrial membrane potential (Figure
19). Furthermore, data with I9.2 cells, a caspase-8 deficient cell, demonstrate no
significant decreases in DNA fragmentation when compared to their parental Jurkat
cells (Figure 17). Together, this data validates that HDACi in combination with
adaphostin induce cell death in ALL through the intrinsic apoptotic pathway.
As mentioned before, the mechanism by which the agent combined with HDACi
functions also plays a role in how the cell death is induced. The present study used
adaphostin that has been shown to induce apoptosis in different hematological
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malignancies and solid tumors [112, 117]. Adaphostin is a tyrosine kinase inhibitor
originally developed to target BCR/ABL positive cells. Svingen et al. demonstrated
that adaphostin activates the apoptotic intrinsic pathway in K562 and blast CML
patient samples. Treatment with adaphostin resulted in release of cytochrome c from
the mitochondrial, and activation of caspases-9 and -3 [135]. Transfecting cells with a
cDNA encoging dominant-negative caspase-9 inhibited the apoptotic changes
observed. However, these changes were not inhibited with the transfection of cells
with cDNA encoding dominant-negative FADD or with treatment of the blocking
antibody anti-Fas [135]. These results demonstrated that adaphostin induce apoptosis
via the intrinsic pathway.

These observations are consistent with our results

demonstrating the involvement of the intrinsic apoptotic pathway in the synergistic cell
death induced by adaphostin and HDACi. Other studies support these results not only
in BCR/ABL positive cells but also in BCR/ABL negative cells [113].
More detailed studies demonstrated that the main mechanism by which
adaphostin induces cell death in different cancer cells is through the production of
ROS [113]. These increases in ROS have been shown to be the direct effect of
adaphostin binding to complex III of the mitochondrial electron transport chain [114].
In addition, studies have demonstrated that adaphostin has the ability to alter different
antioxidant levels like GSH, glutathione S-transferase, superoxide dismutase and
heme oxygenase-1 [113, 116, 117]. Consistent with these results, we demonstrated
that ALL cells treated with low concentrations of adaphostin alone resulted in a loss of
mitochondrial membrane potential starting at eight hours (Figure 18). Increased levels
of superoxide and caspase activation at sixteen hours followed this event (Figure 15,
20). Furthermore, the combination of adaphostin with two different HDACi (vorinostat
and entinostat) resulted in potentiation of all these events.
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Interestingly, several studies have demonstrated that different HDACi have the
potential to induce oxidative stress in different cancer cells.

These observations

directed us to investigate the role of oxidative stress in the synergy between HDACi
and adaphostin, which is discussed in the next section.

Induction of oxidative stress by the combination of HDACi and adaphostin.
In order to investigate if oxidative stress plays a role in HDACi and adaphostin
synergy, we measured superoxide levels in cells treated with the synergistic
combinations.

Time course experiments demonstrated that both combinations

potentiated superoxide levels starting at sixteen hours of treatment (Figure 20). This
data is consistent with observations by others, where adaphostin and different HDACi
used as a single agent induce oxidative stress in cancer cells.

Ruefli et al.

demonstrated that lymphoblastic leukemia cells treated with HDACi resulted in upregulation of the pro-apoptotic gene Bid. The expression of Bid resulted in disruption
of the mitochondria and an increase in ROS levels [87].

Similarly, Rosato et al.

demonstrated that HDACi induce ROS in leukemia cells resulting in DNA damage and
cell death [75, 108].

Furthermore, several studies combining HDACi with other

chemotherapeutic agents have demonstrated a significant increase in oxidative stress
in different cancer cells [108-110].
Previous studies have shown that adaphostin depletes GSH levels resulting in
accumulation of ROS and subsequent cell death in leukemic cells [113]. Similarly,
You et al. demonstrated that the HDACi trichostatin A induced depletion of GSH,
which resulted in an increase in superoxide levels and cell death in HeLa cells [136].
More recently, studies combining the agent PEITC, which has been shown to deplete
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GSH, with vorinostat also resulted in ROS accumulation and induction of apoptosis in
a vorinostat resistant cell line [137].
In order to elucidate if GSH plays an important role in the mechanism by which
HDACi and adaphostin induce oxidative stress, we measured the levels of GSH in
cells treated with the synergistic concentrations of HDACi and adaphostin. Unlike
previous studies, adaphostin alone did not affect GSH levels (Figure 22).

This

discrepancy can be explained by the concentration used in the previous study, where
cells were treated with 10 µM of adaphostin for three hours. In contrast in the present
study, the highest concentration used was 750 nM for twenty-four hours. In addition,
the previous study used CML cells compared to the present study where we used ALL
cells, in which the drug can act by different mechanisms. Similarly to adaphostin,
vorinostat alone failed to decrease GSH levels.

However, the combination of

vorinostat plus adaphostin slightly decreased GSH levels when compared to vorinostat
alone.

Interestingly, entinostat alone decreased the GSH levels and was further

decreased by the combination with adaphostin. However, the decrease in GSH failed
to achieve statistical significance in all treatments (Figure 20).

This differences

between vorinostat and entinostat can be explained by the concentration used, being
0.5 µM for vorinostat and 2.5 µM for entinotat. In addition the specificity of the HDACi
can be involved in this differences. Future studies can explore the relation of HDACi
treatment concentrations and the inhibition of specific HDAC with the regulation of
GSH as antioxidant.
Additional experiments using pre-treatment of GSHee followed by the
synergistic combinations of HDACi and adaphostin, demonstrated increases in GSH
levels (Figure 23).

However, these increases failed to block the mitochondrial
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disruption and the DNA fragmentation observed by the treatment of both combinations
(Figure 23). Based on these results, we can speculate that GSH is not a major player
in the induction of oxidative stress by the combination of HDACi and adaphostin.
However, we cannot discard the possibility of GSH depletion working in conjunction
with other sources of ROS.
To further investigate the role of oxidative stress in the synergy of HDACi and
adaphostin, we used the antioxidant NAC. Pre-treatment with NAC followed by the
synergistic combinations of HDACi and adaphostin resulted in a significant inhibition of
superoxide levels, demonstrating that NAC is working by blocking ROS (Figure 21 A).
In addition, DNA fragmentation was significantly inhibited in cells pre-treated with NAC
and followed by the treatment of vorinostat plus adaphostin (Figure 21 C).
Interestingly, this inhibition was not observed in cells treated with entinostat plus
adaphostin (Figure 21 C).

These results were consistent with data assessing

caspase-3 activation in cells pre-treated with NAC followed by the drug combination
(Figure 21 D). An explanation for these results might be that induction of ROS plays
an important role in the combination of vorinostat and adaphostin but not in the
combination of entinostat and adaphostin.

However, pre-treatment with NAC

decreased superoxide levels and reversed the loss of mitochondrial potential in both
combinations (Figure 21 A-B). Together, the data generated using NAC, suggest that
vorinostat and entinostat in combination with adaphostin might have a different
mechanism by which induce oxidative stress mediated-apoptosis.
Another mechanism by which HDACi might induce oxidative stress has been
linked to their ability to affect the antioxidant Trx. In this case bladder, prostate and
breast cancer cells treated with vorinostat resulted in an up-regulation of thioredoxin
binding protein (TBP-2), which has been demonstrated to bind to the antioxidant Trx
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and inhibit its activity [92]. Furthermore, Ungerstedt and colleagues demonstrated that
multiple myeloma and SV-40 transformed cells treated with vorinostat or entinostat
resulted in ROS-dependent apoptosis.

However, normal human lung and breast

fibroblast cells treated with HDACi resulted in elevated levels of Trx [93].

These

elevations in Trx were correlated to HDACi resistance in normal cells. siRNA towards
Trx sensitized normal cells to HDACi [93]. More recently in vivo studies demonstrated
that vorinostat can change the oxidation state of Trx toward a more oxidized state,
which correlated with decreases in enzymatic activity [138].

These studies

demonstrated that Trx plays a role in the ROS induction by HDACi.
We tested the possibility of Trx to be involved in the synergy between HDACi
and adaphostin.

Contrary to previous studies we found that the synergistic

combinations did not affect TBP-2 mRNA levels (Appendix). We cannot discard the
role of Trx in the combination of HDACi and adaphostin, since this combination can
affect Trx using a different mechanism other than via TBP-2.

Recent data

demonstrate that HDACi induce acetylation of Trx [62]. However, if the acetylation of
Trx affects its activity is not known.

To test this possibility, we measured Trx

acetylation in cells treated with HDACi and adaphostin. Interestingly, in our model,
entinostat induced Trx acetylation and this acetylation was further increased with the
combination of entinostat and adaphostin. However this level of Trx acetylation was
not observed in cells treated with vorinostat and adaphostin (Figure 24).

Control

samples treated with higher concentrations of vorinostat (5 µM) resulted in acetylation
of Trx. This observation demonstrated that one of the differences in Trx acetylation
induced by vorinostat plus adaphostin or entinostat plus adaphostin is the
concentrations used in each combination. The low concentration of 0.5 µM vorinostat
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used in combination with adaphostin did not result in Trx acetylation. In contrast, 2.5
µM entinostat used in combination with adaphostin resulted in increased Trx
acetylation. In order to test if Trx acetylation can be linked to its enzymatic inhibition,
we measured Trx activity in cells treated with the synergistic combinations. We found
that the combination of adaphostin with HDACi did not affect Trx activity (Figure 24).
Together this data suggests that Trx is not a major source for the induction of ROS by
HDACi and adaphostin combinations. However, these experiments were performed
looking at Trx1. Trx has three different isoforms, Trx-1, Trx-2 and Trx-3. Trx-1 and
Trx-2 work mainly as antioxidants. Trx-1 works mainly in the cytosol, where as Trx-2 is
more directed to the mitochondria [22].
specifically study Trx-2.
combination.

Future studies need to be directed to

This will help to elucidate if Trx-2 plays a role in this

Furthermore, additional studies may reveal if different HDACi have

better affinity for one of the Trx isoforms, which has not been studied yet.
In order to better elucidate the possible sources of ROS and to understand the
differences between both combinations, we performed a gene array examining the
expression of different human genes involved in oxidative stress.

Results

demonstrated a differential regulation of genes induced by the combination of
adaphostin-entinostat and adapostin-vorinostat combinations (Table 1). Differences
between the combination of vorinostat plus adaphostin and entinostat plus adaphostin
were analyzed.

Some genes differently affected by one combination versus the

second combination include aldehyde oxidase 1, peroxiredoxin-6, metallothionein,
angiopoietin-like 7 and glutathione peroxidase-6.
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Aldehyde oxidase 1 (AOX1) is one of the genes that can be linked to a possible
mechanism by which the combination of entinostat plus adaphostin differs from the
combination of vorinostat plus adaphostin.

AOX1 is member of the molybdenum

hydroxylase family, which also includes xanthine oxireductase [139, 140]. Its major
function is to catalize the oxidative hydroxylation of different substrates including:
nitrogen-containing heterocyclic compounds, aliphatic and aromatic aldehydes.

Its

actual physiological substrate is unclear but recent data support its involvement in the
metabolism of certain drugs and the detoxification of xenobiotics [139, 140].
In addition to catalize the oxidative hydroxylation, AOX1 also can function as an
oxidase transferring electrons to oxygen resulting in the production of superoxide and
hydrogen peroxide [139, 140]. Our array data demonstrates that AOX1 is 5.6 fold
upregulated in cells treated with the combination of entinostat plus adaphostin. In
contrast no changes were observed in cells treated with vorinostat plus adaphostin.
Since AOX1 has been associated with the production of superoxide this suggests a
possible mechanism by which entinostat plus adaphostin induces superoxide. To the
present and to our understanding there is no data showing the effect of NAC in the
production of ROS by AOX1. It will be interesting to test the effect of NAC in AOX1.
AOX1 can be a possible mechanism in which NAC do not affect its action explaining
the differences in inhibition of DNA fragmentation observed only in the combination of
vorinostat plus adaphostin and not in entinostat plus adaphostin. Presently there is no
a direct correlation between expression of AOX1 and cancer. However as mentioned
before, studies has implicate this enzyme with the metabolism of different drugs.
Some of these drugs include tamoxifen, methortrexate and 6-mercaptopurine [139].
Studies suggest that AOX1 compete with cytochrome P450, which is a phase I

77

enzyme involved in the metabolism of different drugs and xenobiotics [140]. These
observations support the involvement of AOX1 in the metabolism of drugs.
Recent data published by Maeda and colleagues demonstrated that AOX1
gene is regulated by Nrf2 which binds to the ARE element located in the 5’-upstream
region of the AOX1 gene resulting in its expression. This was observed upon the
exposure to electrophilic agents [141].

Interestingly, Wang et al. reported Nrf2

activation by HDACi resulting in neuroprotection [142]. It will be interesting to study
the relation of HDACi, Nrf2 and AOX1 in the combination of entinostat plus
adaphostin.

Efficacy of HDACi and adaphostin in vivo studies
Several in vivo studies have demonstrated the efficacy of vorinostat in
combination with other chemotherapies for the treatment of different types of cancer
[143-145]. These studies use different doses and schedules, ranging from 50 mg/kg
daily to 200 mg/kg daily. These differences can be explained by the use of different
types of cancer xenografts. In addition, the route of administration in these studies
vary with intraperitoneal injections being the most commonly used. Using a transgenic
mouse model of acute promyelocytic leukemia, He, et al. demonstrated that daily
administration for four weeks of 50 mg/kg vorinotat in combination with 1.5 mg/kg
retinoic acid, resulted in increased survival compared to single agent administration
[143]. In a second study, daily administration of 150 mg/kg of vorinostat significantly
inhibited the growth of fribrosarcoma cells in athymic nude mice. Furthermore, this
inhibition was dramatically increased by the combination of 2.2 mg/kg of doxorubicin,
demonstrating

again

the

efficacy

of

vorinostat

in

combination

with

other

chemotherapies [144].
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The main objective of the in vivo studies performed in this study, was to
investigate if the synergy observed between vorinostat and adaphostin can be
recapitulated in vivo. In general, nude mice have been used as an in vivo model for
solid tumors.

In contrast NOD/SCID mice have been used for hematological

malignancies, demonstrating to be more effective in this type of cancer [146]. Using
different NOD/SCID models we studied the synergy of vorinostat in combination with
adaphostin.
First, we used NOD-SCID-IL-2Rgnull mice, which were injected with 100,000
Molt-4 cells per mice. Directed by previous finding in the literature, we selected the
drug dose. Mice were treated thrice weekly with 125 mg/kg of vorinostat [124], 50
mg/kg of adaphostin [125] or the combination of these doses. Results demonstrated
that cell engraftment occurred at week four post-inoculation (Figure 26). After one
week of drug administration, mice treated with adaphostin died suddenly. Subsequent
experiments demonstrated that high doses of adaphostin administrated frequently
could induce gastrointestinal (GI) toxicity (Figure 27). Interestingly, mice treated with
the combination remained alive for four weeks, suggesting a possible antagonistic
effect between the two drugs. After four weeks, we observed a decrease in cell count
in mice treated with vorinostat and the combination compared to control mice.
However all mice died at the same time due to leukemia. Based on these results we
cannot draw any conclusions.
Since we suspected adaphostin toxicity, we decided to decrease the dose to 25
mg/kg of adaphostin and 50 mg/kg of vorinostat.

In a second pilot study using

NOD/SCID mice, the previously mentioned doses were administrated alone or in
combination five days a week. In this occasion we observed GI toxicity in mice treated
with adaphostin or the combination after two week of treatment. Decreased doses of
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12.5 mg/kg of adaphostin delayed the GI toxicity. In this occasion we started to see GI
toxicity again after six weeks of treatments. In term of cells engraftment, we did not
observe any engraftment.
For the first time, we report here, GI toxicity as a result of adaphostin treatment
administrated at 25 mg/kg daily for two weeks. Limited in vivo studies have been
reported using adaphostin. Li et al. studied the pharmacokinetics of adaphostin using
plasma from different models [125]. These models included mice, rats, dogs and
human plasma. They found that adaphostin was most stable in human and murine
plasma. In addition, mice were treated with 50 mg/kg of adaphostin using different
routes of administration. They concluded that bioavailability following intraperitoneal
administration was greater than other administration routes [125]. Based on these
observations we selected the adaphostin dose and administration route. However we
observed high toxicity using this dose. This discrepancy can be explained by the
treatment duration and the mouse strain. The previous study treated CD2F1 mice
once at high doses (50 mg/kg) for a few hours [125]; in contrast we treated NOD-SCID
mice at 25 mg/kg thrice for a week.
Toxicity tests using different adaphostin doses and administration schedule
helped us to elucidate the best dose and schedule resulting in 8 mg/kg of adaphostin
administering thrice weekly.

This dose was consistent with previous studies

administrating adaphostin in a glioblastoma orthotopic model [147]. Finally, this dose
was combined with 50 mg/kg of vorinostat, which was administered for five days a
week, resulting in no sign of toxicity.
We observed cell engraftment in NOD-SCID-IL-2Rgnull mice after four weeks
post-injection. However, NOD/SCID and NOD-Cg-Rag1 mice failed to achieve Molt-4
engraftment. Even though studies have demonstrated that NOD/SCID and mice with
80

Rag-1 mutations are better for leukemia engraftments, some factors in these mice can
affect the engraftment of cancer cells.

Hudson and colleagues performed a

comparison between Nude, SCID, NOD/SCID and Rag-1 deficient mice [148]. They
injected different cells from lymphoid malignancies, including Molt-4.

The results

demonstrated that NOD/SCID mice had better engraftment compared to the other
mouse strains [148]. However, in contrast to our model, they injected 1 x 107 Molt-4
cells subcutaneously instead of intravenously. Furthermore, in order to optimize tumor
growth, they mixed Molt-4 cells with HT1080 fibrosarcoma cells [148].

While

subcutaneous injections allow rapid tumor growth, this model does not provide the
tumor microenvironment to accurately model the disease, which can result in falsepositive results.

In contrast, orthotopic models, where tumor growth arises in the

tissue of origin, can mimic the disease with more accurately [149].
Our results demonstrated that NOD-SCID-IL-2Rgnull mice had better cell
engraftment compared to NOD/SCID or NOD-Cg-Rag1. Even when NOD/SCID and
Rag negative mice lack from the majority of the immune system components, they can
still possess low levels of natural killer (NK) cells.

In addition, studies have

demonstrated that with aging these mice can develop high levels of immunoglobulin,
which resulted in decreased engraftment [150]. Furthermore, engraftment of T-lineage
ALL cells has lower success rates compared to B-lineage cells in these mice [151]. In
contrast to NOD/SCID mice, NOD-SCID-IL-2Rgnull completely lack NK cells, which
make this a better model for T-ALL cell engraftment [152].
For future directions, the use of NOD-SCID-IL-2Rgnull mice is recommended.
As a second option and in order to improvement the chances of Molt-4 cells
engraftment in NOD/SCID mice, Molt-4 can be mixed with HT1080 fibrosarcoma cells.
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This last approach has been proven to enhance the cell engraftment [151, 153]. In
addition, further immunosuppression can be achieved using irradiation [148].

Conclusion and future directions
In summary, we found that for the first time the ROS generating agent
adaphostin synergizes with two different HDACi (vorinostat and entinostat) in ALL
cells. Importantly, the synergistic concentration did not affect normal PBMC,
demonstrating that this effect is selective for T-ALL cells.

This synergy is mainly

driven by the activation of the intrinsic apoptotic pathway, where time course analysis
showed that perturbation of the mitochondrial membrane potential is the earliest event
observed. Following this event, increasing levels of superoxide, caspase activation
and ultimately cell death were observed.
Pre-treatment with the antioxidant N-acetylcysteine (NAC) blocked ROS
generation and reversed the loss of mitochondrial membrane potential in both
combinations. However, apoptosis was only blocked by NAC in cells treated with
vorinostat-adaphostin; but not with entinostat-adaphostin, suggesting that these
combinations work by different redox mechanisms.

Previous adaphostin and/or

HDACi targets, like Trx, GSH, were tested to try to elucidate the source of oxidative
stress in these combinations. We concluded that Trx and GSH are not the major
source of ROS in these combinations.

However gene array data, examining the

expression of genes involved in oxidative stress, resulted in genes differentially
regulated between cells treated with vorinostat-adaphostin and entinostat-adaphostin.
These target genes includes: aldehyde oxidase 1, peroxiredoxin-6, metallothionein,
angiopoietin-like 7 and glutathione peroxidase-6. From these a promising candidate to
follow-up is aldehyde oxidase 1. This gene is involved in the production of superoxide
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and drugs metabolism. This was upregulated in the combination of entinostat plus
adaphostin but not changes were observed in the combination of vorinostat plus
adaphostin.
Future directions include the validation of the different genes, specially AOX1,
which were differentially regulated between both combinations. Results from these
experiments will help to explore different pathways that can be affected by these
combinations. In addition the development of an in vivo model is of utmost importance
to test the clinical relevance of HDACi plus adaphostin combinations for the treatment
of T-ALL.

Suggestions will be to employ the initially used NOD-SCID-IL-2Rgnull

mouse model with the dose regimens characterized in our toxicity test. In addition, the
use of ALL patient samples can be used as a second alternative to test if HDACi
synergize with adaphostin.
Understanding the mechanism involved in these combinations will advance
scientific knowledge of how the action of HDACi could be augmented in leukemia
models. Moreover, this information could be used for the development of effective
clinical trials combining HDACi with other anticancer agents.
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APPENDIX:

Figure A1. Synergistic combinations do not affect XIAP.
5 x 106 Jurkat cells were treated with the synergistic
combinations of 0.5 µM Ada and 0.5 µM Vori or 0.75 µM Ada
and 2.5 µM Enti or either agent alone. After 24 h of
incubation cells were harvested and protein lysates were
prepared. XIAP and total actin were measured by Western
blot.

Figure A2. TBP-2 expression in cells treated with the
synergistic combinations at 4 h and 8 h. 5 x 106 Jurkat
cells were treated with the synergistic combinations of 0.5
µM Ada and 0.5 µM Vori or 0.75 µM Ada and 2.5 µM Enti.
After 4 h and 8 h cells were harvested and RT-PCR for
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